09 December 2021
EMA/CHMP/711196/2021
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 11-14 October 2021

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore, not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See October 2021 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 11-14 October 2021.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present remotely). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Slovenian member gave a PROXY to the Austrian member for the CHMP meeting, held 11-14 October 2021.

1.2. Adoption of agenda

CHMP agenda for 11-14 October 2021

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 13-16 September 2021

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 04 October 2021.

The CHMP minutes for 13-16 September 2021 were adopted via written procedure on 21 October 2021.

The CHMP adopted the minutes from the PROM meeting held on 04 October 2021.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. bevacizumab - EMEA/H/C/005433

indicated in adults for the treatment of neovascular macular degeneration associated with aging and diabetes

Scope: Oral explanation

Action: Oral explanation to be held on 12 October 2021 at 14:00

List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 17.09.2020.

An oral explanation was held on Tuesday 12 October 2021. The presentation by the applicant focused on the clinical data in support of the application.

2.1.2. avacopan - Orphan - EMEA/H/C/005523

Vifor Fresenius Medical Care Renal Pharma France; Treatment of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

Scope: Oral explanation

Action: Oral explanation to be held on 12 October 2021 at 16:00

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.02.2021.

An oral explanation was held on Tuesday 12 October 2021. The presentation by the applicant focused on the clinical data in support of the application.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

2.4.1. Lidocain/ Prilocain IDETEC – lidocaine, prilocaine - EMEA/H/A-29(4)/1506

International Drug Development France

Referral Rapporteur: Kristine Moll Harboe, Co-Rapporteur: Paula Boudewina van Hennik

Scope: Oral explanation

Action: Oral explanation to be held on 12 October 2021 at 11:00

Summary: Decentralised Procedure number: DK/H/3106/001/DC, notification by the Danish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MS is of the opinion that therapeutic equivalence has not been demonstrated between the test and the reference product.

List of questions adopted on 25.03.2021.

An oral explanation was held on 12 October 2021. The presentation by the applicant focused on data in support of the therapeutic equivalence between the test and the reference product.

See 10.04

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Aspaveli - pegcetacoplan - Orphan - EMEA/H/C/005553

Swedish Orphan Biovitrum AB (publ); paroxysmal nocturnal haemoglobinuria (PNH)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.09.2021, 24.06.2021. List of Questions adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that pegcetacoplan is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.2. Cibinqo - abrocitinib - EMEA/H/C/005452

Pfizer Europe MA EEIG; Indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.09.2021, 24.06.2021. List of Questions adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that abrocitinib is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.3. Rybrevant - amivantamab - EMEA/H/C/005454

Janssen-Cilag International N.V.; for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on 20.05.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that amivantamab is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 15 October 2021.

The summary of opinion was circulated for information.

3.1.4. Sitagliptin SUN - sitagliptin fumarate - EMEA/H/C/005741

Sun Pharmaceutical Industries Europe B.V.; treatment of type 2 diabetes mellitus

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Januvia

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.5. Trodelvy - sacituzumab govitecan - EMEA/H/C/005182

Gilead Sciences Ireland UC; treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.09.2021. List of Questions adopted on 22.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 8 October 2021.

The summary of opinion was circulated for information.

3.1.6. Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477

Merck Sharp & Dohme B.V.; immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on 22.04.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - ATMP - EMEA/H/C/004731

Bristol-Myers Squibb Pharma EEIG; treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

Scope: List of outstanding issues

Action: For information

List of Outstanding Issues adopted on 16.04.2021. List of Questions adopted on 06.11.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee endorsed a 2nd list of outstanding issues with a specific timetable, as adopted by CAT.

3.2.2. gefapixant - EMEA/H/C/005476

treatment of refractory or unexplained chronic cough

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.06.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.3. gefapixant - EMEA/H/C/005884

treatment of refractory or unexplained chronic cough

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.06.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678

treatment of type 2 diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.03.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. voxelotor - Orphan - EMEA/H/C/004869

Global Blood Therapeutics Netherlands; Indicated for the treatment of haemolytic anaemia in adults and paediatric patients 12 years of age and older with sickle cell disease (SCD).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.05.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. anifrolumab - EMEA/H/C/004975

indicated as an add-on therapy for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), despite standard therapy

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.02.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

The CHMP agreed to consult an ad-hoc expert group and adopted a list of questions to this group.

3.2.7. sapropterin - EMEA/H/C/005646

treatment of hyperphenylalaninemia (HPA)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.05.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. semaglutide - EMEA/H/C/005422

treatment for weight loss and weight maintenance

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.05.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. copanlisib - Orphan - EMEA/H/C/004334

Bayer AG; treatment of adult patients with relapsed marginal zone lymphoma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. dimethyl fumarate - EMEA/H/C/005956

treatment of multiple sclerosis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. dimethyl fumarate - EMEA/H/C/005955

treatment of multiple sclerosis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. maribavir - Orphan - EMEA/H/C/005787

Shire Pharmaceuticals Ireland Limited; treatment of cytomegalovirus (CMV) infection

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. tezepelumab - EMEA/H/C/005588

add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. faricimab - EMEA/H/C/005642

treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. arachis hypogaea extract - Article 28 - EMEA/H/C/004810

treatment of peanut allergy

Scope: Request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in July 2021.

Action: For adoption

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.02.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in July 2021.

3.4.2. betaine anhydrous - EMEA/H/C/005637

treatment of homocystinuria

Scope: Letter from the applicant dated 30 September 2021 requesting an extension to the clock stop to respond to the list of questions adopted in April 2021.

Action: For adoption

List of Questions adopted on 22.04.2021.

The CHMP did not agree to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in April 2021.

3.4.3. ganirelix - EMEA/H/C/005641

Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).

Scope: Letter from the applicant dated 22 September 2021 requesting an extension to the clock stop to respond to the list of questions adopted in July 2021.

Action: For adoption

List of Questions adopted on 22.07.2021

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in July 2021.

3.4.4. hepatitis B surface antigen - EMEA/H/C/005466

indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

Scope: Letter from the applicant dated 07 October 2021 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in September 2021.

Action: For adoption

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on

22.04.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in September 2021.

3.4.5. lonafarnib - Orphan - EMEA/H/C/005271

EigerBio Europe Limited; treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies

Scope: Letter from the applicant dated 04 October 2021 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in September 2021.

Action: For adoption

List of Outstanding Issues adopted on 16.09.2021, 25.02.2021. List of Questions adopted on 23.07.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in September 2021.

3.4.6. arimoclomol - Orphan - EMEA/H/C/005203

Orphazyme A/S; treatment of Niemann-Pick disease type C (NPC)

Scope: Letter from the applicant dated 23 September 2021 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in September 2021.

Action: For adoption

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on 25.03.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in September 2021.

3.4.7. bevacizumab - EMEA/H/C/005574

Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.
First-line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: Letter from the applicant dated 28 September 2021 requesting an extension to the clock stop to respond to the list of questions adopted in April 2021.

Action: For adoption

List of Questions adopted on 22.04.2021

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in April 2021.

3.4.8. enfortumab vedotin - EMEA/H/C/005392

treatment of locally advanced (LA) or metastatic urothelial cancer (mUC)

Scope: Letter from the applicant dated 27 September 2021 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in September 2021.

Action: For adoption

List of Outstanding Issues adopted on 14.09.2021. List of Questions adopted on 22.06.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in September 2021.

3.4.9. sugammadex - EMEA/H/C/005760

Reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Scope: Letter by the applicant dated 30 September 2021 requesting an extension to the clock stop to respond to list of questions adopted in July 2021.

Action: For adoption

List of Questions adopted on 22.07.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to list of questions adopted in July 2021.

3.4.10. autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - ATMP - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: Letter from the applicant dated 06 October 2021 requesting an extension to the clock stop to respond to the list of outstanding issues adopted on in July 2021.

Action: For information

List of Outstanding Issues adopted on 16.07.2021. List of Questions adopted on 22.01.2021.

The CHMP endorsed the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in July 2021, as adopted by CAT.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Nexviadyme - avalglucosidase alfa - Orphan - EMEA/H/C/005501

Genzyme Europe BV; for long-term enzyme replacement therapy for the treatment of patients with Pompe disease.

Scope: List of experts for the Ad-hoc expert group (AHEG) meeting, List of questions to the AHEG

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

The CHMP agreed to consult an Ad-hoc expert group (AHEG) and adopted a list of questions to this group together with a list of experts.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Flynpovi - eflornithine / sulindac - Orphan - EMEA/H/C/005043

Cancer Prevention Pharma (Ireland) Limited; treatment of adult patients with familial adenomatous polyposis (FAP)

Scope: Withdrawal of marketing authorisation application

Action: For information

Fixed combination application (Article 10b of Directive No 2001/83/EC)

Opinion adopted on 24.06.2021. List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 15.10.2020.

The CHMP noted the withdrawal of the marketing authorisation application.

3.7.2. Zynyz - retifanlimab - Orphan - EMEA/H/C/005632

Incyte Biosciences Distribution B.V.; Treatment of locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of questions adopted on 24.06.2021

The CHMP noted the withdrawal of the marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Comirnaty - tozinameran - EMEA/H/C/005735/X/0044/G

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst

Scope: Extension application to add a new pharmaceutical form (dispersion for injection) with a new strength (0.1 mg/ml).
Update of sections 6.4, 6.5 and 6.6 of the SmPC, section 5, 6 and information for healthcare professionals of the PL, section 1 of the Carton Box Label as well as section 1 and 5 of the Vial Label to ensure the correct handling by providing dose verification information about strength, age range, colour information of the flip-off plastic cap and greyscale images.
Update of section 4.2 of the SmPC to ensure the correct handling in accordance to interchangeability of the medicinal product.
Update of section 8 of Carton Box Label to clarify expiry date "EXP" by adding storage temperature "(at -90°C to -60°C)" to ensure the correct handling of the medicinal product.
Change the name of the active substance from COVID-19 mRNA Vaccine (nucleoside modified) to Tozinameran.
The marketing authorisation holder has taken the opportunity to implement minor editorial changes.

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.2. Nitisinone MDK - nitisinone - EMEA/H/C/004281/X/0007

MendeliKABS Europe Limited

Rapporteur: Alar Irs, PRAC Rapporteur: Ilaria Baldelli

Scope: "Extension application to add a new strength of 20 mg (hard capsule)."

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 17.09.2020.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.3. Trydonis - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004702/X/0015

Chiesi Farmaceutici S.p.A.

Rapporteur: Janet Koenig, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension application to add a new pharmaceutical form (inhalation powder) associated with new strength (88 µg / 5 µg / 9 µg). The RMP (version 7.1) is updated in accordance."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Ferriprox - deferiprone - EMEA/H/C/000236/X/0145

Chiesi Farmaceutici S.p.A.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension application to introduce a new pharmaceutical form (gastro-resistant tablets). The RMP (version 14.0) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 24.06.2021, 25.02.2021. List of Questions adopted on 17.09.2020.

The Committee discussed the issues identified in this application, relating to quality aspects and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the 3rd list of outstanding issues and a specific timetable.

4.2.2. Kaftrio - ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA/H/C/005269/X/0008/G

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

Scope: "Extension application to introduce new strengths of 37.5 mg/ 25 mg/ 50 mg film-coated tablets. Grouped with a type II variation (C.I.6.a) to include paediatric use (6 to 11 years)."

Action: For adoption

List of Questions adopted on 22.07.2021.

The Committee discussed the issues identified in this application, relating to the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.3. Ozempic - semaglutide - EMEA/H/C/004174/X/0021

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Annika Folin

Scope: "Extension application to add a new strength of 2 mg solution for injection."

Action: For adoption

List of Questions adopted on 20.05.2021.

The Committee discussed the issues identified in this application, relating to quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G

Gilead Sciences Ireland UC

Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to introduce a new strength 30/120/15 mg. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric indication: use in patients 2 years of age and older and weighing at least 14 kg. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.1) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions and a specific timetable.

4.3.2. Lyumjev - insulin lispro - EMEA/H/C/005037/X/0010

Eli Lilly Nederland B.V.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Annika Folin

Scope: Quality variation "The RMP is updated (version 11.1) accordingly."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions and a specific timetable.

4.3.3. Sogroya - somapacitan - Orphan - EMEA/H/C/005030/X/0001/G

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

Scope: "Extension application to add a new strength of 5 mg/1.5 mL (3.3 mg/mL) grouped with a Type II Quality variation and a Type IA variation. The RMP was updated (version 2.0) accordingly.
Type II variation (B.II.b.1.c)
Type IA variation (B.II.d.1.a)."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions and a specific timetable.

4.3.4. Zejula - niraparib - Orphan - EMEA/H/C/004249/X/0029

GlaxoSmithKline (Ireland) Limited

Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension application to introduce a new pharmaceutical form (100 mg film-coated tablet). The RMP (version 5.1) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions and a specific timetable.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Cosentyx - secukinumab - EMEA/H/C/003729/II/0079

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: "C.I.6 (Extension of indication)
Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy for Cosentyx; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.2. Entyvio - vedolizumab - EMEA/H/C/002782/II/0061

Takeda Pharma A/S

Rapporteur: Armando Genazzani, PRAC Rapporteur: Adam Przybylkowski

Scope: "To add a new therapeutic indication "treatment of adult patients with pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with, lost response to, or were intolerant to antibiotic therapy" for Entyvio 300 mg (powder for concentrate for solution for infusion), based on final results from study Vedolizumab-4004 (ERNEST). This was an interventional, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Entyvio (intravenous) in the treatment of chronic pouchitis.

As a consequence, sections 4.1, 4.2, 4.5, 5.1 and 5.2 of the SmPC for Entyvio 300 mg are updated. The Package Leaflet are updated in accordance. Version 7.0 of the RMP is also submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0129

CSL Behring GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to expand the approved secondary immunodeficiencies (SID) indications to any symptomatic SID in accordance with the Guideline on core SmPC for human normal immunoglobulin for intravenous administration (EMA/CHMP/BPWP/94038/ 2007 Rev 5; CHMP, 2018). As a consequence, sections 4.1 and 4.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.6 of the RMP has been accepted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.
The variation leads to amendments to the Summary of Product Characteristics, Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.4. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0096

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication for Kalydeco tablets in combination regiment with Kaftrio to include the treatment of adults, adolescents and children aged 6 years and older with cystic fibrosis who are homozygous for the F508del mutation in the CFTR gene or heterozygous for F508del and have a minimal function (MF) mutation in the CFTR gene. This application is based on the results of study VX18-445-106, a phase 3, open-label, multicentre study in subjects 6 through 11 years of age, with F/MF and F/F genotypes. As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The Packaged Leaflet is updated in

accordance. Version 12.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.07.2021.

The Committee discussed the issues identified in this application, relating to the product information.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.5. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0104

Merck Sharp & Dohme B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include Keytruda in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 32.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 16.10.2021, 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0105

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 33.0 of the RMP has also been agreed."

Action: For adoption

Request for Supplementary Information adopted on 16.09.2021, 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0108

Merck Sharp & Dohme B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "C.I.6.a Update of sections 4.1, 4.2 and 5.1 of the SmPC in order to extend the existing therapeutic indications for Keytruda to include the adjuvant treatment in monotherapy of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. The Package Leaflet is updated accordingly. The RMP version 35.1 has also been submitted"

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0109

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Keytruda as monotherapy in the treatment of unresectable or metastatic MSI-H or dMMR colorectal, endometrial, gastric, small intestine, biliary, or pancreatic cancer in adults who have received prior therapy. The proposed indication is based on the results from the KEYNOTE-164 (KN164) and KEYNOTE-158 (KN158) trials. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (Version 34.1) has been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.9. Kineret - anakinra - EMEA/H/C/000363/II/0086

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Fátima Ventura, PRAC Rapporteur: Anette Kirstine Stark

Scope: "C.I.6 - Extension of indication to include treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia who are at risk of developing severe

respiratory failure for Kineret; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.6 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.10. Kisplyx - lenvatinib - EMEA/H/C/004224/II/0045

Eisai GmbH

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include Kisplyx in combination with pembrolizumab first line treatment of adults with advanced renal cell carcinoma (RCC); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted. In addition, the Marketing authorisation holder took the opportunity to make editorial changes and update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 16.10.2021, 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP noted the letter of recommendations dated 11 October 2021.

The summary of opinion was circulated for information.

5.1.11. Lenvima - lenvatinib - EMEA/H/C/003727/II/0042

Eisai GmbH

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 14.1 of the RMP has also been agreed. In addition, the MAH took the opportunity to make minor editorial changes to the SmPC, Annex II and to update the list of local representatives in the Package Leaflet in line with the latest QRD template version 10.2. Furthermore, the request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004) was granted."

Action: For adoption

Request for Supplementary Information adopted on 16.09.2021, 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.12. Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G

Teva B.V.

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age appropriate presentation in vials; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Action: For adoption

Request for Supplementary Information adopted on 12.11.2020.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.13. Olumiant - baricitinib - EMEA/H/C/004085/II/0028

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Adam Przybylkowski

Scope: "C.I.6 - Extension of indication to include treatment of coronavirus disease 2019 (COVID 19) in hospitalised adult and paediatric patients aged 10 years and older who require low-flow oxygen or non-invasive ventilation/high flow oxygen for Olumiant; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Annex II and the Package Leaflet are updated in accordance. Version 11.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 22.07.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information.

The CHMP agreed to the request by the applicant for an extension of the clock stop to respond to the request for supplementary information.

5.1.14. Repatha - evolocumab - EMEA/H/C/003766/II/0049/G

Amgen Europe B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Kimmo Jaakkola

Scope: "C.I.6
Extension of indication to include one new paediatric indication in paediatric patients aged 10 years and over with heterozygous familial hypercholesterolaemia as an adjunct to diet, alone or in combination with other lipid-lowering therapy, to reduce LDL-C based on results of study 20120123 (HAUSER-RCT). It is a randomized, multicenter, placebo-controlled, double blind, parallel group, 24-week trial in 158 paediatric patients aged 10 to > 18 years with heterozygous familial hypercholesterolaemia. As a consequence, sections 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet are updated in accordance. Version 7.0 of the RMP has also been submitted.
C.I.6
Extension of indications to modify the existing indication for treatment of adults and paediatric patients aged 10 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies based on interim results from study 20120124 (HAUSER-OLE). It was an open label, single arm, multicenter, 80-week trial to evaluate the safety, tolerability and efficacy of Repatha for LDL-C reduction in paediatric patients from aged ≥ 10 to < 18 years of age with homozygous familial hypercholesterolaemia. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.15. RoActemra - tocilizumab - EMEA/H/C/000955/II/0101

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "C.I.6 - Extension of indication to include the treatment of coronavirus disease 2019 in hospitalised adults who are receiving systemic corticosteroids and require supplemental

oxygen or mechanical ventilation for RoActemra; as a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.8, 5.1 and 5.2 of the SmPC for RoActemra 20 mg/mL concentrate for solution for infusion are updated. The Package Leaflet is updated in accordance. Version 27 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev. 1."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.16. Senshio - ospemifene - EMEA/H/C/002780/II/0041

Shionogi B.V.

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication by deletion of information on specific subset of patients for Senshio. This is supported by the submission of the final study report of the imposed non-interventional post-authorisation safety study. As mentioned in Annex IID, this is an observational retrospective cohort study of ospemifene to assess the incidence of venous thromboembolism and other safety concerns as agreed in the Risk Management Plan (RMP), in vulvar and vaginal atrophy (VVA) patients treated with ospemifene compared to 1) patients newly prescribed SERMs for oestrogen-deficiency conditions or breast cancer prevention, and 2) the incidence in untreated VVA patients. As a consequence, sections 4.1 and 4.4 of the SmPC are updated. The Package Leaflet and Annex IID are updated in accordance. Version 2 of the RMP has also been submitted. In addition, the Marketing authorisation holder took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

The Committee discussed the issues identified in this application, relating to the SmPC.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. Skyrizi - risankizumab - EMEA/H/C/004759/II/0014

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Peter Kiely, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "New therapeutic indication for the treatment of active psoriatic arthritis in adults. Consequently, sections 4.1, 4.2, 4.8, 5.1 and 5.2 to the SmPC have been updated. The Package leaflet is updated accordingly. Minor update of Annex II is also introduced. The RMP is also updated accordingly. The variation leads to amendments to the Summary of Product Characteristics, Annex II, Labelling and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.18. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0064

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "C.I.6 (Extension of indication)
Extension of indication to include adjuvant treatment of non-small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy for adult patients whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TC) for Tecentriq as monotherapy based on the results from the pivotal phase III study GO29527 (IMpower010); as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of both the Tecentriq 840 mg concentrate for solution for infusion SmPC and the Tecentriq 1,200 mg concentrate for solution for infusion SmPC are updated. Minor editorial changes have been made throughout the SmPC. The Package Leaflets are updated in accordance. Version 21.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.19. Verzenios - abemaciclib - EMEA/H/C/004302/II/0013

Eli Lilly Nederland B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include Verzenios in combination with endocrine therapy for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence; as a consequence, section 4.1, 4.2, 4.4, 4.6, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021, 25.02.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.20. Xeljanz - tofacitinib - EMEA/H/C/004214/II/0035

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension of indication to include treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy for Xeljanz film-coated tablets; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 17.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 20.05.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.21. Zeposia - ozanimod - EMEA/H/C/004835/II/0002/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Bruno Sepodes, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "C.I.6.a (Extension of indication)
Extension of indication to include the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent for Zeposia; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and Annex IID are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes throughout the product information. Version 2.1 of the RMP has been approved.
C.I.4
Update of sections 4.4 and 4.5 of the SmPC in order to update the current SmPC description about PK interaction with BCRP inhibitors based on the study report from a drug interaction study with cyclosporine l(RPC-1063-CP-001).
The group of variations leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 22.07.2021, 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.22. Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0036

Merck Sharp & Dohme B.V.

Rapporteur: Ingrid Wang, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include treatment of paediatric patients aged birth to less than 18 years for Zerbaxa, based on final results from studies MK-7625A-034 (A Phase 2, Randomized, Active Comparator-Controlled, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Paediatric Subjects with Complicated Urinary Tract Infection, Including Pyelonephritis) and MK-7625A-035 (A Phase 2, Randomized, Active Comparator-Controlled, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Paediatric Subjects with Complicated Intra-Abdominal Infection).
As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.23. WS1952 Edistride - dapagliflozin - EMEA/H/C/004161/WS1952/0042 Forxiga - dapagliflozin - EMEA/H/C/002322/WS1952/0060

AstraZeneca AB

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication for Forxiga / Edistride to include treatment of children aged 10 years and adolescents with T2DM based on the results from studies MB10209/D1690C000016 and MB102-138/D1690C00017; these are paediatric studies submitted according to Article 46 of the Paediatric Regulation. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 21 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Xalkori - crizotinib - EMEA/H/C/002489/II/0072

Pfizer Europe MA EEIG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension of indication to include treatment of paediatric patients (age ≥ 6 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumour (IMT) for XALKORI based on the results from studies ADVL0912 and A8081013; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the ATC code for crizotinib. Moreover, the MAH took the opportunity to implement a minor change in the list of local representatives in the Package Leaflet."

Scope: Letter from the applicant dated 28 September 2021 requesting an extension to the clock stop to respond to the request for supplementary information adopted in September 2021.

Action: For adoption

Request for Supplementary Information adopted on 16.09.2021.

The CHMP agreed to the request from the applicant for an extension to the clock stop to respond to the request for supplementary information adopted in September 2021.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. fosdenopterin - H0005378

Treatment of patients with molybdenum cofactor deficiency (MoCD) Type A

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.2. spesolimab - H0005874

Treatment of flares in adult patients with generalised pustular psoriasis (GPP)

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.

8.2.1. List of applications received

Action: For information

The CHMP noted the information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 6 recommendations for eligibility to PRIME: 1 was accepted and 5 were denied.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0026

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to include updated efficacy and safety information based on primary analysis from study D8110C00001 listed as a specific obligation in Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicenter study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria; the Package Leaflet and Annex II are updated accordingly. The updated RMP Version 3 Succession 4 is approved."

Action: For adoption

Request for Supplementary Information adopted on 16.09.2021, 22.07.2021

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

9.1.2. Pramipexole Accord - pramipexole - EMEA/H/C/002291

Accord Healthcare S.L.U.; treatment of idiopathic Parkinson's disease and treatment of idiopathic Restless Legs Syndrome

Rapporteur: Ingrid Wang

Scope: Withdrawal of marketing authorisation

Action: For information

Generic application (Article 10(1) of Directive No 2001/83/EC)

The CHMP noted the withdrawal of marketing authorisation.

9.1.3. Equidacent – bevacizumab – EMEA/H/C/005181

Centus Biotherapeutics; treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer; first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer; first line treatment of patients with advanced and/or metastatic renal cell cancer.

Rapporteur: Ingrid Wang, Co-Rapporteur: Outi Mäki-Ikola

Scope: Withdrawal of marketing authorisation

Action: For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

The CHMP noted the withdrawal of marketing authorisation.

9.1.4. Klisyri - tirbanibulin - EMEA/H/C/005183/ANX/001

Rapporteur: Peter Kiely, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Michal Radik

CHMP request for PRAC advice on PASS protocol assessment

The CHMP is requesting PRAC advice for the protocol assessment of study M-14789-41, a phase 4, multi-centre, randomised, investigator-blinded, active controlled, parallel-group study, requested by CHMP to further investigate the risk of progression of actinic keratosis to squamous cell carcinoma in adult patients with non-hyperkeratotic, non-hypertrophic actinic keratosis treated with tirbanibulin.

Action: For adoption

The CHMP adopted the request for PRAC advice.

9.1.5. Impact of tocilizumab potential shortages on CAR-T cell-based ATMPs use in EU – regulatory options and recommendations

Scope: Scientific and regulatory considerations regarding the treatment of cytokine release syndrome following CAR-T cell administration.

Action: For discussion

The CHMP noted the update.

9.1.6. Leganto – Rotigotine – EMA/H/C/002380

UCB Pharma S.A.

Rapporteur: Bruno Sepodes, Co-Rapporteur: Johann Lodewijk Hillege

Scope: Notification letter of MA received on 05.10.2021 informing of a marketing cessation in DE in Q2/Q3 2022 for commercial reasons

Action: For information

The CHMP noted the cessation on Germany in Q2/Q3 2022.

9.1.7. Invokana - canagliflozin - EMEA/H/C/002649/II/0055

Janssen-Cilag International NV

Rapporteur: Martina Weise

Scope: Update to sections 4.2 and 5.1 of the Invokana SmPC to amend posology information concerning the treatment of patients with eGFR between ⩾30 and <45 mL/min/1.73 m2, whether or not albuminuria is present; the update is based on further analysis of previously submitted CANVAS data (studies DIA3008 and DIA4003). The Applicant has also taken the opportunity to make minor editorial changes to section 4.5.

Action: For adoption

Request for Supplementary Information adopted on 22.04.2021, 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.8. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0030/G

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "This is an extension application to add a new strength (22 mg prolonged-release tablet) grouped with a type II variation C.I.4: Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC to include the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent; as an alternative to the immediate release film-coated tablets; section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of UC. The Package Leaflet is updated accordingly. The RMP version 15.1 has also been submitted."

Letter from the MAH dated 05.10.2021 informing of the withdrawal of the extension application

Action: For information

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on 25.02.2021.

The CHMP noted the withdrawal of the extension application.

9.1.9. Nulojix - belatacept - EMEA/H/C/002098/II/0065/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Filip Josephson

Scope: Quality variation

Action: For discussion

Request for Supplementary Information adopted on 25.03.2021, 12.11.2020, 12.03.2020.

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted a 4th request for supplementary information with a specific timetable.

9.1.10. Visudyne - verteporfin – EMEA/H/C/000305

CHEPLAPHARM Arzneimittel GmbH

Rapporteur: Alexandre Moreau, Co-Rapporteur: Kirstine Moll Harboe

Scope: Shortage - Adoption of a DHPC.

Action: For adoption

The CHMP adopted the DHPC.

9.1.11. Kevzara – Sarilumab – EMEA/H/C/004254

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus

Scope: Shortage - Proposal for a DHPC to be adopted via written procedure after the meeting

Action: For information

The CHMP noted the DHPC which was adopted on 19 October 2021 via written procedure.

9.1.12. Presence of the nitrosamine N-nitroso-varenicline in Champix – EMEA/H/C/000699

Pfizer Europe MA EEIG

Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Johann Lodewijk Hillege

Scope: Updated DHPC was adopted via written procedure on 21.09.2021

Action: For information

At an extraordinary CHMP meeting on 23 September 2021, the updated DHPC, which was adopted via written procedure on 21.09.2021, was circulated for information. The CHMP noted the updated DHPC.

9.1.13. COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified)- EMEA/H/C/005735/II/0062

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: Update of sections 4.2 and 4.4 of the SmPC in order to introduce a third dose of Comirnaty for individuals 12 years of age and older who are severely immunocompromised,

based on published literature data; the Package Leaflet is updated accordingly.

Action: For adoption

At an extraordinary CHMP meeting on 04 October 2021, the CHMP discussed this variation.

The Committee confirmed that all issues previously identified in this application had been addressed.

On 04 October 2021, the Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.14. COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified)- EMEA/H/C/005735/II/0067

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to introduce a booster dose (third dose) of Comirnaty for individuals 18 years of age and older, based on interim safety and immunogenicity data from the interventional study C4591001, " A Phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals". The package leaflet is updated accordingly.

Action: For adoption

At an extraordinary CHMP meeting on 04 October 2021, the CHMP discussed this variation.

The Committee confirmed that all issues previously identified in this application had been addressed.

On 04 October 2021, the Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.15. Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0031

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: Update of sections 4.2 and 4.4 of the SmPC in order to introduce a third dose of Spikevax in the primary vaccination schedule for individuals 12 years of age and older who are severely immunocompromised, based on published literature data; the Package Leaflet is updated accordingly. The MAH took the opportunity to make minor administrative and editorial corrections throughout the product information.

Action: For adoption

At an extraordinary CHMP meeting on 04 October 2021, the CHMP discussed this variation.

The Committee confirmed that all issues previously identified in this application had been addressed.

On 04 October 2021, the Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Nasolam – midazolam - EMEA/H/A-29(4)/1511

Tiofarma B.V

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kristina Dunder

Scope: Appointment of Rapporteurs, List of Questions, Timetable

Action: For adoption

Decentralised procedure number: NL/H/5089/001-003/DC, notification by the Agency of the Netherlands dated 24 September 2021 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC

The CHMP appointed Johann Lodewijk Hillege as Rapporteur and Kristina Dunder as Co-Rapporteur.

The CHMP adopted a list of questions with a specific timetable.

Start of procedure (CHMP): October 2021 CHMP

List of Questions: 14.10.2021

Submission of responses: 09.12.2021

Re-start of the procedure: 30.12.2021

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 07.01.2022

Comments: 14.01.2022

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 20.01.2022

CHMP opinion or CHMP LoOI: January 2022 CHMP

10.4.2. Lidocain/ Prilocain IDETEC – lidocaine, prilocaine - EMEA/H/A-29(4)/1506

International Drug Development France

Referral Rapporteur: Kristine Moll Harboe, Co-Rapporteur: Paula Boudewina van Hennik

Scope: Oral explanation

Action: Oral explanation to be held on 12 October 2021 at 11:00

Summary: Decentralised Procedure number: DK/H/3106/001/DC, notification by the Danish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MS is of the opinion that therapeutic equivalence has not been demonstrated between the test and the reference product.

List of questions adopted on 25.03.2021.

See 2.4

An oral explanation was held on 12 October 2021. The presentation by the applicant focused on data in support of the therapeutic equivalence between the test and the reference product.

The CHMP adopted a negative opinion by majority, recommending that the marketing authorisations for the medicinal products concerned should be refused.

The divergent position was appended to the opinion.

The questions-and-answer document was circulated for information.

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. STRESAM and generics – etifoxine (hydrochloride) - EMEA/H/A-31/1509

Various

Referral Rapporteur: John Joseph Borg, Co-Rapporteur: Simona Badoi (collaboration with Bulgaria)

Scope: list of outstanding issues

Action: For adoption

Summary: ANSM has triggered a referral under Article 31 of Directive 2011/83/EC to review the B/R balance of etifoxine containing products, in light of the new results from the AMETIS study.

The CHMP adopted a list of outstanding issues with a specific timetable.

CHMP list of outstanding issues: 14.10.2021

Submission of responses: 09.12.2021

Re-start of the procedure: 30.12.2021

Rapporteur/co-rapporteur joint assessment report(s)circulated to CHMP: 07.01.2022

Comments: 14.01.2022

Updated Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 20.01.2022

OE/CHMP opinion/list of outstanding issues: January 2022 CHMP

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

October 2021 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Election of new CHMP vice-chair

Bruno Sepodes has served as vice-chair of the CHMP since 19 October 2018 and his first 3-year mandate will shortly come to an end.

Candidature(s) received

The CHMP re-elected Bruno Sepodes as CHMP Vice-chair for a 3 year mandate, starting 15. October 2021.

14.1.2. Structured guidance on reflection of use of extrapolation - development of an assessor's guidance template

This document reflects on the published reflection paper on the use of extrapolation of efficacy and safety data in the development of medicines, with a focus on paediatrics.

Action: For discussion

The CHMP noted the guidance document.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for October 2021

Action: For adoption

The CHMP adopted the EURD list.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/ Sean Barry

Election of a new BWP vice-chair. Nanna Aaby Kruse (DK) has resigned from her position as BWP vice-chair following the September 2021 meeting.

Candidature(s) received

Action: For adoption

The CHMP elected Sean Barry (IE) as new BWP Vice-chair.

Reports from BWP October 2021 meeting to CHMP for adoption:

- 22 reports on products in scientific advice and protocol assistance
- 9 reports on products in pre-authorisation procedures
- 2 reports on products in post-authorisation procedures

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Safety Working Party (SWP)

Chairs: Jan Willem Van der Laan/Susanne Brendler-Schwaab

Election of a new SWP chair. Jan Willem Van der Laan's second term will expire on 18 October 2021.

Candidature(s) received

Action: For adoption

The CHMP elected Susanne Brendler-Schwaab as new SWP chair.

14.3.3. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 16-17 September 2021.

Action: For adoption

The CHMP adopted the table of decisions.

14.3.4. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 27-30 September 2021. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.5. Scientific Advice Working Party Products related (SAWP)

IMI-PREFER Qualification Opinion

Action: For adoption

The CHMP adopted the IMI-PREFER Qualification Opinion presented to the CHMP during the 6th September PROM meeting.

14.3.6. Working Party implementation project

Update on the project

Action: For information

The CHMP noted the update.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

14.7.1. Supplementary Urgency Procedures for Regulatory Assessment (SUPRA)

Update on the progress of SUPRA initiative which is currently part of the CHMP work plan 2021. Feedback from Workshop which took place on 22 September 2021.

Action: For information

The CHMP noted the update.

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the update.

15.1.2. Sotrovimab - EMEA/H/0005676

Treatment of coronavirus disease 2019 (COVID-19)

Scope: interim opinion on 3rd rolling review

Action: For adoption

At an extraordinary CHMP meeting on 23 September 2021, the CHMP discussed the 3rd rolling review interim opinion.

On 23 September 2021, the Committee adopted a positive interim opinion on the 3rd rolling review by consensus.

The Norwegian CHMP member was in agreement with the CHMP recommendations.

15.1.3. Joint CHMP/CAT Strategic Review & Learning meeting (CHMP/CAT SRLM) under the Slovenian presidency

CHMP: Nevenka Trsinar Brodt, Kristina Nadrah

Action: For information

The CHMP noted the agenda for the joint CHMP/CAT Strategic Review & Learning meeting under the Slovenian presidency.

Lists of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 11-14 October 2021 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	COVID-19 vaccines
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Helen Vella	Alternate	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Grzegorz Cessak	Alternate	Poland	No participation in final deliberations and voting on	COVID-19 vaccines
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Vincent Gazin	Expert - via WebEx*	France	No interests declared	
Margaux TIBERI	Expert - via WebEx*	France	No interests declared	
Anissa Benlazar	Expert - via WebEx*	France	No interests declared	
Juha Vakkilainen	Expert - via WebEx*	Finland	No interests declared	
Pauliina Lehtolainen-Dalkilic	Expert - via WebEx*	Finland	No interests declared	
Antero Kallio	Expert - via Webex*	Finland	No restrictions applicable to this meeting	
Elina Asikanius	Expert - via Webex*	Finland	No restrictions applicable to this meeting	
Eeva Sofia Leinonen	Expert - via WebEx*	Finland	No interests declared	
Saila Antila	Expert - via WebEx*	Finland	No interests declared	
Taina Methuen	Expert - via WebEx*	Finland	No interests declared	
Agnieszka Przybyszewska	Expert - via WebEx*	Ireland	No interests declared	
Benita Cullen	Expert - via WebEx*	Ireland	No interests declared	
Catherine Byrne	Expert - via WebEx*	Ireland	No interests declared	
Marcela Juarez Hernandez	Expert - via WebEx*	Germany	No restrictions applicable to this meeting	
Susanne Mueller-Egert	Expert - via WebEx*	Germany	No interests declared	
Hilke Zander	Expert - via WebEx*	Germany	No interests declared	
Anja Schmidt	Expert - via WebEx*	Germany	No interests declared	
Paula Contreras Alarcón	Expert - via WebEx*	Spain	No participation in discussion, final deliberations and voting on	Skyrizi - risankizumab - EMEA/H/C/004759 /II/0014
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Macarena Rodriguez Mendizabal	Expert - via WebEx*	Spain	No interests declared	
Alida Spruijt	Expert - via WebEx*	Netherlands	No interests declared	
Laura Rodwell	Expert - via WebEx*	Netherlands	No interests declared	
Sanna Gevers	Expert - via WebEx*	Netherlands	No interests declared	
Ingrid Schellens	Expert - via WebEx*	Netherlands	No interests declared	
Jaap Fransen	Expert - via WebEx*	Netherlands	No interests declared	
Stavros Nikolakopoulos	Expert - via WebEx*	Netherlands	No interests declared	
Sujata Sengupta	Expert - via WebEx*	Netherlands	No interests declared	
Loes den Otter	Expert - via WebEx*	Netherlands	No interests declared	
Peter Caspers	Expert - via WebEx*	Netherlands	No interests declared	
Hanneke Mulder	Expert - via WebEx*	Netherlands	No interests declared	
Richard IJzerman	Expert - via WebEx*	Netherlands	No participation in discussion, final deliberations and voting on	WS1952 Edistride/Forxiga
Chantal van de Schootbrugge	Expert - via WebEx*	Netherlands	No interests declared	
Patrick Vrijlandt	Expert - via WebEx*	Netherlands	No interests declared	
Victoriia Starokozhko	Expert - via WebEx*	Netherlands	No restrictions applicable to this meeting	
Liesbeth Van Vlijmen	Expert - via WebEx*	Netherlands	No interests declared	
Quirine Fillekes	Expert - via WebEx*	Netherlands	No interests declared	
Maria Grünewald	Expert - via WebEx*	Sweden	No interests declared	
Anna Vikerfors	Expert - via WebEx*	Sweden	No interests declared	
Sabine Mayrhofer	Expert - via WebEx*	Germany	No interests declared	
Irene Bachmann	Expert - via WebEx*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via WebEx*	Germany	No interests declared	
Norbert Benda	Expert - via WebEx*	Germany	No interests declared	
Mette Linnert Jensen	Expert - via WebEx*	Denmark	No interests declared	
Meera Varma	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Anne-Marie Dalseg	Expert - via WebEx*	Denmark	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Nanna Borup Johansen	Expert - via WebEx*	Denmark	No interests declared	
Lene Weber Vestermark	Expert - via WebEx*	Denmark	No interests declared	
Kristin Skougaard	Expert - via WebEx*	Denmark	No interests declared	
Deidre Mannion	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Kristina Bech Jensen	Expert - via WebEx*	Denmark	No interests declared	
Anne Hasle Buur	Expert - via WebEx*	Denmark	No interests declared	
Sidsel Arnspang Pedersen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Sine Buhl Naess-Schmidt	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Mette Tranholm	Expert - via WebEx*	Denmark	No interests declared	
Mette Toftegaard Madsen	Expert - via WebEx*	Denmark	No interests declared	
Thalia Marie Estrup Blicher	Expert - via WebEx*	Denmark	No participation in discussion, final deliberations and voting on	semaglutide - EMEA/H/C/005422 Ozempic - semaglutide - EMEA/H/C/004174 /X/0021
Andreas James Schaeffer Senders	Expert - via WebEx*	Denmark	No interests declared	
Marianne Løiten Dalhus	Expert - via WebEx*	Norway	No interests declared	
Caroline Gjestad	Expert - via WebEx*	Norway	No interests declared	
Ingebjørg Buajordet	Expert - via WebEx*	Norway	No interests declared	
Ingrid Lund	Expert - via WebEx*	Norway	No interests declared	
Valerie Lescrainier	Expert - via WebEx*	Belgium	No interests declared	
Olga Kholmanskikh	Expert - via WebEx*	Belgium	No interests declared	
Stefan Bonné	Expert - via WebEx*	Belgium	No interests declared	
Edwige Haelterman Brenneisen	Expert - via WebEx*	Belgium	No interests declared	
Violette Dirix	Expert - via WebEx*	Belgium	No interests declared	
Filip Van Nuffel	Expert - via WebEx*	Belgium	No interests declared	
Yseult Brun	Expert - via WebEx*	France	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maria Grazia Evandri	Expert - via WebEx*	Italy	No interests declared	
Cristina Migali	Expert - via WebEx*	Italy	No interests declared	
Paolo Foggi	Expert - via WebEx*	Italy	No interests declared	
Adriana Ammassari	Expert - via WebEx*	Italy	No interests declared	
Odoardo Maria Olimpieri	Expert - via WebEx*	Italy	No interests declared	
Antonella Isgrò	Expert - via WebEx*	Italy	No interests declared	
Barbara Bonamassa	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Sarah Galluzzo	Expert - via WebEx*	Italy	No interests declared	
Valentina Conti	Expert - via WebEx*	Italy	No interests declared	
Robert Nistico	Expert - via WebEx*	Malta	No interests declared	
Stephanie Liane Cini	Expert - via WebEx*	Malta	No interests declared	
Zsuzsanna Sasvari	Expert - via WebEx*	Hungary	No interests declared	
Anja Schiel	Expert - via WebEx*	Norway	No interests declared	
Hans Van Gompel	Expert - via WebEx*	Netherlands	No interests declared	
Rou-Afza Gunput	Expert - via WebEx*	Netherlands	No interests declared	
Wilhelm Johan de Waard	Expert - via WebEx*	Netherlands	No interests declared	
Roel Van Loock	Expert - via WebEx*	Belgium	No interests declared	
Kairi Rooma	Expert - via WebEx*	Estonia	No interests declared	
Martina Schuessler-Lenz	Expert - via WebEx*	Germany	No interests declared	
Julio Delgado Gonzalez	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Sandrine Chiappini	Expert - via WebEx*	France	No interests declared	
Sophie Teng	Expert - via WebEx*	France	No interests declared	
Nuno Rocha-Pereira	Expert - via WebEx*	Portugal	No restrictions applicable to this meeting	
Carlos Alves	Expert - via WebEx*	Portugal	No interests declared	
Concetta Quintarelli	Expert - via WebEx*	Italy	No interests declared	
Stephanie Buchholz	Expert - via WebEx*	Germany	No interests declared	
Elisabeth Wischnitzki	Expert - via WebEx*	Austria	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Hannah Münch	Expert - via WebEx*	Austria	No interests declared	
Claudia Afonso	Expert - via WebEx*	Portugal	No restrictions applicable to this meeting	
Nele Steens	Expert - via WebEx*	Belgium	No interests declared	
Benjamin Micallef	Expert - via WebEx*	Malta	No interests declared	
Kim Sherwood	Expert - via WebEx*	Sweden	No interests declared	
Anne Karin Rehnström	Expert - via WebEx*	Sweden	No interests declared	
Jennifer ten Kulve	Expert - via WebEx*	Netherlands	No interests declared	
Susanne Brendler-Schwaab	Expert - via WebEx*	Germany	No interests declared	
Suzana Vidic	Expert - via WebEx*	Slovenia	No restrictions applicable to this meeting	
Megan Hickie	Expert - via WebEx*	TGA	No interests declared	
Filip Kukulski	Expert - via WebEx*	Health Canada	No interests declared	
Meeting run with the help of EMA staff				

*Experts were evaluated against the product(s) they have been invited to talk about

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the extraordinary CHMP meeting held on 23 September 2021.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Konstantinos Markopoulos	Member	Greece	No interests declared	
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Elita Poplavska	Member	Latvia	No interests declared	
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Kairi Rooma	Expert - via Webex*	Estonia	No interests declared	
Deirdre Mannion	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Sine Buhl Naess-Schmidt	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Bibi Fatima Syed Shah	Expert - via Webex*	Denmark	No interests declared	
Nanna Borup Johansen	Expert - via Webex*	Denmark	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Signe Pedersen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Paula Contreras Alarcón	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Sabine Mayrhofer	Expert - via Webex*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via Webex*	Germany	No interests declared	
Theis Moeslund Jensen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Maeve Lally	Expert - via Webex*	Ireland	No restrictions applicable to this meeting	
Mair Powell	Expert - via Webex*	Ireland	No interests declared	
Charlotte Geluk	Expert - via WebEx*	Swissmedic	No interests declared	
Mohit Khera	Expert - via WebEx*	TGA Australia	No interests declared	

*Experts were evaluated against the product(s) they have been invited to talk about

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the extraordinary CHMP meeting held on 4 October 2021.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda and for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda and for which restrictions apply
Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	COVID-19 vaccines
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Adriana Ammassari	Expert - via WebEx*	Italy	No interests declared	
Mette Tranholm	Expert - via WebEx*	Denmark	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda and for which restrictions apply
Deirdre Mannion	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Yuansheng Sun	Expert - via WebEx*	Germany	No interests declared	
Kristina Karlsson	Expert - via Webex*	Sweden	No restrictions applicable to this meeting	
Andreas Kirisits	Expert - via WebEx*	Austria	No interests declared	
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Paula Contreras Alarcón	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Elisabeth Øya	Expert - via WebEx*	Norway	No interests declared	
Svein Rune Andersen	Expert - via WebEx*	Norway	No interests declared	
Charlotta Bergquist	Expert - via WebEx*	Sweden	No interests declared	
Helena Faust	Expert - via WebEx*	Sweden	No interests declared	
Jessica Mwinyi	Expert - via WebEx*	Sweden	No interests declared	
Annette Lommel	Expert - via WebEx*	Germany	No interests declared	
Violette Dirix	Expert - via WebEx*	Belgium	No interests declared	
Heidi Meyer	Expert - via WebEx*	Germany	No interests declared	
Anja Schiel	Expert - via WebEx*	Norway	No interests declared	
Nora Cascante Estepa	Expert - via WebEx*	Germany	No interests declared	
Sabine Mayrhofer	Expert - via WebEx*	Germany	No interests declared	
Meeting run with the help of EMA staff				

*Experts were evaluated against the product(s) they have been invited to talk about

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications

follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures

can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

09 December 2021
EMA/CHMP/712615/2021

Annex to 11-14 October 2021 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for October 2021: **For adoption**	Adopted

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for October 2021: **For adoption**	Adopted

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Chenodeoxycholic acid Leadiant - chenodeoxycholic acid - EMEA/H/C/004061/S/0017, Orphan Leadiant GmbH, Rapporteur: Konstantinos Markopoulos, PRAC Rapporteur: Adam Przybylkowski Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
MVABEA - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005343/S/0006 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
Qarziba - dinutuximab beta - EMEA/H/C/003918/S/0028, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
ZABDENO - ebola vaccine (rDNA, replication-incompetent) -	Positive Opinion adopted by consensus together with the CHMP assessment report.

EMEA/H/C/005337/S/0005 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné	The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

AMGEVITA - adalimumab - EMEA/H/C/004212/R/0029 Amgen Europe B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Chenodeoxycholic acid Leadiant - chenodeoxycholic acid - EMEA/H/C/004061/R/0018, Orphan Leadiant GmbH, Rapporteur: Konstantinos Markopoulos, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Rolufta Ellipta - umeclidinium - EMEA/H/C/004654/R/0019 GlaxoSmithKline Trading Services Limited, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ilaria Baldelli Request for Supplementary Information adopted on 14.10.2021, 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Roteas - edoxaban - EMEA/H/C/004339/R/0021 Berlin Chemie AG, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Tiphaine Vaillant	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can

	be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/R/0035 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Ilaria Baldelli Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Xeljanz - tofacitinib - EMEA/H/C/004214/R/0040 Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.

B.2.3. Renewals of Conditional Marketing Authorisations

COMIRNATY - tozinameran - EMEA/H/C/005735/R/0046 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 16.09.2021.	Positive Opinion adopted by consensus together with the CHMP assessment. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
CRYSVITA - burosumab - EMEA/H/C/004275/R/0026, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Brigitte Keller-Stanislawski	Positive Opinion adopted by consensus together with the CHMP assessment. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Holoclar - ex vivo expanded autologous	Positive Opinion adopted by consensus together

human corneal epithelial cells containing stem cells - EMEA/H/C/002450/R/0039, Orphan, ATMP Holostem Terapie Avanzate s.r.l., Rapporteur: Egbert Flory, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Rhea Fitzgerald	with the CHMP assessment. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Polivy - polatuzumab vedotin - EMEA/H/C/004870/R/0008, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Annika Folin Request for Supplementary Information adopted on 16.09.2021.	Positive Opinion adopted by consensus together with the CHMP assessment. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
RETSEVMO - selpercatinib - EMEA/H/C/005375/R/0008 Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst	Positive Opinion adopted by consensus together with the CHMP assessment. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/R/0037 AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné	Positive Opinion adopted by consensus together with the CHMP assessment. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection PRAC recommendations on signals adopted at the PRAC meeting held on 27-30 September 2021 PRAC:	
Signal of erythema multiforme Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst PRAC recommendation on a variation **Action:** For adoption	Adopted
Signal of erythema multiforme Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Hans Christian Siersted PRAC recommendation on a variation **Action:** For adoption	Adopted
Signal of immune thrombocytopenia Vaxzevria - COVID-19 Vaccine (ChAdOx1-S [recombinant]) Rapporteur: Sol Ruiz, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné PRAC recommendation on a variation, DHPC, Communication plan – adopted via written procedure on 1 October 2021 **Action:** For information	Noted
PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its September 2021 meeting:	

EMEA/H/C/PSUSA/00000918/202103 (dabigatran) CAPS: **Pradaxa** (EMEA/H/C/000829) (dabigatran etexilate), Boehringer Ingelheim International GmbH, Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Anette Kirstine Stark, "18/03/2020 To: 18/03/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add adverse reaction "anticoagulant-related nephropathy" should be performed. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00000998/202103 (dexmedetomidine) CAPS: **Dexdor** (EMEA/H/C/002268) (dexmedetomidine), Orion Corporation, Rapporteur: Filip Josephson NAPS: **NAPs** - EU PRAC Rapporteur: Ulla Wändel Liminga, "16/03/2020 To: 15/03/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction diabetes insipidus with a frequency unknown, and a warning on diabetes insipidus. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00002182/202101 (estradiol / nomegestrol acetate) CAPS: **Zoely** (EMEA/H/C/001213) (nomegestrol acetate / estradiol), Theramex Ireland Limited, Rapporteur: Jean-Michel Race NAPS: **NAPs** - EU PRAC Rapporteur: Tiphaine Vaillant, "26/01/2018 To: 26/01/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.4 of the SmPC to add warnings on the drug-drug interaction with glecaprevir/pibrentasvir in the case of patients suffering from hepatitis C, as well as on the exacerbation of symptoms of hereditary and acquired angioedema. Update of section 4.5 of the SmPC with details on the drug-drug interaction with glecaprevir/pibrentasvir. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00002435/202102 (pirfenidone) CAPS: **Esbriet** (EMEA/H/C/002154) (pirfenidone), Roche Registration GmbH, Rapporteur: Peter Kiely, PRAC Rapporteur: Rhea Fitzgerald, "27/02/2020 To: 27/02/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the Summary of Product Characteristics to add Stevens Johnson syndrome and Toxic Epidermal Necrolysis with a frequency unknown and a warning in relation to permanent discontinuation of pirfenidone treatment. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00010039/202102 (brentuximab vedotin) CAPS: **ADCETRIS** (EMEA/H/C/002455) (brentuximab vedotin), Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "18/02/2020 To: 18/02/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add a warning and information on the adverse reaction drug reaction with eosinophilia and systemic symptoms (DRESS) and to add a warning and information on the risk of extravasation. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010120/202102 (nalmefene) CAPS: **Selincro** (EMEA/H/C/002583) (nalmefene), H. Lundbeck A/S, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, "24/02/2018 To: 24/02/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.7 and 4.8 of the SmPC to add the adverse reaction 'visual impairment'. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00010127/202102 (pomalidomide) CAPS: **Imnovid** (EMEA/H/C/002682) (pomalidomide), Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Eva A. Segovia, "07/02/2019 To: 07/02/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add solid organ transplant rejection with a frequency 'not known'. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010413/202103 (guanfacine) CAPS: **Intuniv** (EMEA/H/C/003759) (guanfacine), Takeda Pharmaceuticals International AG, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Maria del Pilar Rayon, "18/03/2020 To: 17/03/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a warning on aggression and to amend the warning on suicidal ideation. The Package leaflet is updated accordingly. Update of section 4.8 to include aggression with frequency uncommon ($\geqslant$ 1/1000 to <1/100) taking into account the frequency of the clinical trials. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010758/202103 (fremanezumab) CAPS: **AJOVY** (EMEA/H/C/004833) (fremanezumab), TEVA GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kirsti Villikka, "13/09/2020 To: 13/03/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add adverse reaction "Anaphylactic reaction". The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00010823/202102 (upadacitinib) CAPS: **RINVOQ** (EMEA/H/C/004760) (upadacitinib), AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "15/08/2020 To: 15/02/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction diverticulitis with a frequency uncommon and warning on diverticulitis. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010851/202103 (isatuximab) CAPS: **SARCLISA** (EMEA/H/C/004977) (isatuximab), sanofi-aventis groupe, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Eva A. Segovia, "01/09/2020 To: 01/03/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended together with the detailed explanation of the scientific grounds for the differences with the PRAC recommendation, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 6.6 of the SmPC to clarify the size of the in-line filter to be used for administration following spontaneous report of a medication error case. The package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00010900/202103 (cabotegravir) CAPS: **Vocabria** (EMEA/H/C/004976) (cabotegravir), ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "18/03/2020 To: 17/03/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product, concerning the following change(s): Update of section 4.8 of the SmPC to include "suicidal ideation" and "suicide attempt", both with a frequency "uncommon", followed by "particularly in patients with a pre-existing history of psychiatric illness". The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

B.4. EPARs / WPARs

Artesunate Amivas - artesunate - EMEA/H/C/005550, Orphan Amivas Ireland Ltd, treatment of malaria, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Brukinsa - zanubrutinib - EMEA/H/C/004978, Orphan BeiGene Ireland Ltd, treatment of Waldenström's macroglobulinaemia (WM), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
GAVRETO - pralsetinib - EMEA/H/C/005413 Roche Registration GmbH, treatment of non-small cell lung cancer (NSCLC), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Hukyndra - adalimumab - EMEA/H/C/005548 STADA Arzneimittel AG, treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis, Similar biological application (Article 10(4) of Directive No	For information only. Comments can be sent to the PL in case necessary.

2001/83/EC)	
Libmyris - adalimumab - EMEA/H/C/005947 STADA Arzneimittel AG, treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis, Duplicate, Duplicate of Hukyndra, Similar biological application (Article 10(4) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
QINLOCK - ripretinib - EMEA/H/C/005614, Orphan Deciphera Pharmaceuticals (Netherlands) B.V., Treatment of patients with advanced gastrointestinal stromal tumour (GIST), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Raylumis - tanezumab - EMEA/H/C/005189 Pfizer Europe MA EEIG, treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Rivaroxaban Mylan - rivaroxaban - EMEA/H/C/005600 Mylan Ireland Limited, Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors. Treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrent DVT and PE in adults. Prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery. Generic, Generic of Xarelto, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Sugammadex Mylan - sugammadex - EMEA/H/C/005403 Mylan Ireland Limited, treatment of neuromuscular blockade induced by rocuronium or vecuronium, Generic, Generic of Bridion, Generic application (Article 10(1) of Directive No	For information only. Comments can be sent to the PL in case necessary.

2001/83/EC)	
Vumerity - diroximel fumarate - EMEA/H/C/005437 Biogen Netherlands B.V., treatment of relapsing remitting multiple sclerosis, Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Oportuzumab monatox DLRC Pharma Services - oportuzumab monatox - EMEA/H/C/005730 DLRC Pharma Services Ltd, Treatment and prevention of recurrence of carcinoma-in-situ (CIS) of the urinary bladder and prevention of recurrence of high grade Ta and/or T1 papillary tumours, New active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Ameluz - 5-aminolevulinic acid - EMEA/H/C/002204/II/0049/G Biofrontera Bioscience GmbH, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.
Bavencio - avelumab - EMEA/H/C/004338/II/0028 Merck Europe B.V., Rapporteur: Filip Josephson Opinion adopted on 14.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Buvidal - buprenorphine - EMEA/H/C/004651/II/0015/G Camurus AB, Rapporteur: Peter Kiely Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Cerezyme - imiglucerase - EMEA/H/C/000157/II/0123/G Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.
Cinacalcet Mylan - cinacalcet -	Request for supplementary information adopted

EMEA/H/C/004014/II/0016 Mylan Pharmaceuticals Limited, Generic, Generic of Mimpara, Rapporteur: Tomas Radimersky Request for Supplementary Information adopted on 23.09.2021.	with a specific timetable.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0054/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Grouped Variation: · Type II C.I.11.b, To update Annex II to implement changes and provision of data to fulfill specific obligations SO2f, SO4, and SO5. Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0056/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, " C.I.11.b, (Type II)- To submit additional data to complete characterisation of the active substance and finished product, which are a condition to the Marketing Authorisation (Special Obligation SO1) C.I.11.b, (Type II)- To submit additional data to enhance the control strategy, including the active substance and finished product specifications, which are a condition to the Marketing Authorisation (Special Obligation SO2) Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0071 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 06.10.2021.	Positive Opinion adopted by consensus on 06.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0072/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 11.10.2021.	Positive Opinion adopted by consensus on 11.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0073/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 07.10.2021.	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Drovelis - drospirenone / estetrol - EMEA/H/C/005336/II/0003 Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.), Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 23.09.2021.	Request for supplementary information adopted with a specific timetable.
Drovelis - drospirenone / estetrol - EMEA/H/C/005336/II/0004/G Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.), Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 23.09.2021.	Request for supplementary information adopted with a specific timetable.
Dupixent - dupilumab - EMEA/H/C/004390/II/0050/G sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.
Epidyolex - cannabidiol - EMEA/H/C/004675/II/0014/G, Orphan GW Pharma (International) B.V., Rapporteur: Kirstine Moll Harboe Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 02.09.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
HEPLISAV B - hepatitis B surface antigen - EMEA/H/C/005063/II/0010 Dynavax GmbH, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.
Herceptin - trastuzumab - EMEA/H/C/000278/II/0174/G Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 07.10.2021.	Request for supplementary information adopted with a specific timetable.
Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0019/G Bayer AG, Rapporteur: Kirstine Moll Harboe Request for Supplementary Information adopted on 07.10.2021.	Request for supplementary information adopted with a specific timetable.
Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0011/G, Orphan Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 07.10.2021.	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Request for Supplementary Information adopted on 08.07.2021.	
Kevzara - sarilumab - EMEA/H/C/004254/II/0028/G sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 14.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Lydisilka - drospirenone / estetrol - EMEA/H/C/005382/II/0003 Estetra SRL, Duplicate, Duplicate of Drovelis, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 23.09.2021.	Request for supplementary information adopted with a specific timetable.
Lydisilka - drospirenone / estetrol - EMEA/H/C/005382/II/0004/G Estetra SRL, Duplicate, Duplicate of Drovelis, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 23.09.2021.	Request for supplementary information adopted with a specific timetable.
Neulasta - pegfilgrastim - EMEA/H/C/000420/II/0117 Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 07.10.2021.	Request for supplementary information adopted with a specific timetable.
Nimenrix - Meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/002226/II/0111/G Pfizer Europe MA EEIG, Rapporteur: Ingrid Wang Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Nulojix - belatacept - EMEA/H/C/002098/II/0065/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 14.10.2021, 25.03.2021, 12.11.2020, 12.03.2020.	Request for supplementary information adopted with a specific timetable. See 9.1
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0020/G Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 07.10.2021. Request for Supplementary Information adopted on 08.07.2021.	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Onpattro - patisiran -	Positive Opinion adopted by consensus on

EMEA/H/C/004699/II/0021/G, Orphan Alnylam Netherlands B.V., Rapporteur: Kristina Dunder Opinion adopted on 07.10.2021.	07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Puregon - follitropin beta - EMEA/H/C/000086/II/0122 Organon N.V., Rapporteur: Peter Kiely Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Reagila - cariprazine - EMEA/H/C/002770/II/0020/G Gedeon Richter Plc., Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
Reagila - cariprazine - EMEA/H/C/002770/II/0022 Gedeon Richter Plc., Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
Remicade - infliximab - EMEA/H/C/000240/II/0229 Janssen Biologics B.V., Rapporteur: Kristina Dunder Opinion adopted on 14.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Retacrit - epoetin zeta - EMEA/H/C/000872/II/0105 Pfizer Europe MA EEIG, Rapporteur: Martina Weise Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
RINVOQ - upadacitinib - EMEA/H/C/004760/II/0011 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Silapo - epoetin zeta - EMEA/H/C/000760/II/0065 STADA Arzneimittel AG, Rapporteur: Martina Weise Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Skyrizi - risankizumab - EMEA/H/C/004759/II/0017/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Peter Kiely Request for Supplementary Information adopted on 23.09.2021.	Request for supplementary information adopted with a specific timetable.

Skyrizi - risankizumab - EMEA/H/C/004759/II/0018 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Peter Kiely Opinion adopted on 14.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0035 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 05.10.2021. Request for Supplementary Information adopted on 27.09.2021.	Positive Opinion adopted by consensus on 05.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
TAKHZYRO - lanadelumab - EMEA/H/C/004806/II/0021/G, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Kristina Dunder Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 24.06.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Taltz - ixekizumab - EMEA/H/C/003943/II/0045/G Eli Lilly and Co (Ireland) Limited, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0030/G AstraZeneca AB, Rapporteur: Sol Ruiz Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 30.09.2021, 02.09.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Vazkepa - icosapent ethyl - EMEA/H/C/005398/II/0003 Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise Opinion adopted on 07.10.2021. Request for Supplementary Information adopted on 02.09.2021.	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
VEYVONDI - vonicog alfa - EMEA/H/C/004454/II/0017 Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 23.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

VITRAKVI - larotrectinib - EMEA/H/C/004919/II/0017 Bayer AG, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
WS2044 **Herceptin-EMEA/H/C/000278/WS2044/0171** **MabThera-EMEA/H/C/000165/WS2044/0184** Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 23.09.2021. Request for Supplementary Information adopted on 24.06.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2146 **Nuwiq-EMEA/H/C/002813/WS2146/0046** **Vihuma-EMEA/H/C/004459/WS2146/0028** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 07.10.2021.	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Alunbrig - brigatinib / brigatinib - EMEA/H/C/004248/II/0033/G Takeda Pharma A/S, Rapporteur: Sinan B. Sarac, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information about the effect of brigatinib on the pharmacokinetics of a sensitive cytochrome P450 3A substrate (midazolam) in patients with ALK-positive or ROS1-positive solid tumours based on a clinical study report (study 1001). Update of section 4.2 of the SmPC in order to clarify the existing renal impairment dosage adjustment recommendation based on results of previously submitted studies (clinical study AP26113-15-108, study 108). Update of section 4.2 of the SmPC in order to clarify the existing hepatic impairment dosage adjustment recommendation based on results of previously submitted studies (clinical study AP26113-15-107, study 107). Update of sections 4.4 and 4.5 of the SmPC in order to update drug-drug interaction information regarding concomitant treatment with moderate CYP3A inhibitors or	Request for supplementary information adopted with a specific timetable.

inducers based on results of previously submitted studies (physiologically-based pharmacokinetic (PBPK) report and PBPK report addendum). Update of section 5.1 of the SmPC in order to amend the ATC code; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement a statement regarding the sodium content of Alunbrig in section 4.4 of the SmPC and Package Leaflet. The MAH also took the opportunity to bring the Product Information in line with the latest QRD template (version 10.2 rev.1) and to update the list of local representatives in the Package Leaflet. Moreover, the MAH took the opportunity to introduce minor editorial changes in the PI in different languages." Request for Supplementary Information adopted on 14.10.2021, 22.07.2021.	
Alunbrig - brigatinib / brigatinib - EMEA/H/C/004248/II/0034 Takeda Pharma A/S, Rapporteur: Sinan B. Sarac, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on photosensitivity based on a report of cumulative evidence for an association between exposure to brigatinib and subsequent development of photosensitivity reaction; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make a minor editorial change in section 4.8 of the SmPC." Request for Supplementary Information adopted on 14.10.2021, 22.07.2021.	Request for supplementary information adopted with a specific timetable.
Beovu - brolucizumab - EMEA/H/C/004913/II/0006 Novartis Europharm Limited, Rapporteur: Alexandre Moreau, "Update of section 4.2 of the SmPC to update the wording of the posology, following the assessment of procedure EMEA/H/C/004913/II/0002. In addition, section 4.4 of the SmPC is updated to inform that the interval between two Beovu doses during maintenance treatment should not be less than every 8 weeks as warranted and the Package Leaflet is updated accordingly. Furthermore, the marketing authorisation holder has taken the opportunity to implement minor editorial changes in section 6.5 of the SmPC. Furthermore, the CHMP considered that this	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

variation implements changes to the decision granting the marketing authorisation due to a significant public health concern." Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 25.02.2021.	
Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0105 GSK Vaccines S.r.l, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add lymphadenopathy to the list of adverse drug reactions. The Package Leaflet section 4 is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2 rev1 (including addition of the "sodium-free" statement in the SmPC section 4.4) and update the list of local representatives." Opinion adopted on 07.10.2021.	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Braftovi - encorafenib - EMEA/H/C/004580/II/0020 Pierre Fabre Medicament, Rapporteur: Janet Koenig, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with rosuvastatin and bupropion based on final results from Arm 2 of study ARRAY-818-103. This is a Phase 1, three-arm, open-label drug-drug interaction study in patients with BRAF V600-mutant unresectable or metastatic melanoma or other BRAF V600-E and/or K-mutant advanced solid tumours. The requested variation proposed amendments to the Summary of Product Characteristics. In vivo, encorafenib is an inhibitor of OATP1B1, OATP1B3 and/or BCRP. Co-administration of encorafenib with OATP1B1, OATP1B3 or BCRP substrates (such as rosuvastatin, atorvastatin, methotrexate) can result in increased concentrations. Repeated administration of encorafenib 450 mg once daily and binimetinib 45 mg twice daily with a single dose of rosuvastatin (a OATP1B1, OATP1B3 and BCRP substrate) increased rosuvastatin Cmax by 2.7-fold and AUC by 1.6-fold indicating a mild inhibition of OATP1B1, OATP1B3 and/or BCRP transporters." Opinion adopted on 14.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Brilique - ticagrelor -	Request for supplementary information adopted

EMEA/H/C/001241/II/0054 AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning and new adverse drug reactions on bradyarrhythmia and AV blocks based on a review of all currently available information, including clinical trial data, post marketing reports, and plausible mechanism." Request for Supplementary Information adopted on 14.10.2021.	with a specific timetable.
Calquence - acalabrutinib - EMEA/H/C/005299/II/0006 AstraZeneca AB, Rapporteur: Filip Josephson, "Submission of updated report from study1000-171974-6 in order to provide additional long-term stability data for the metabolite of acalabrutinib ACP-5862." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Calquence - acalabrutinib - EMEA/H/C/005299/II/0007 AstraZeneca AB, Rapporteur: Filip Josephson, "Submission of the final report from ACE-HV-114, an open-label, fixed sequence study in healthy subjects to assess the pharmacokinetics of acalabrutinib and its active metabolite, ACP-5862, when administered alone and in combination with moderate CYP3A4 inhibitors fluconazole or isavuconazole. " Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0062 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2 and 4.4 of the SmPC in order to introduce a third dose of Comirnaty for individuals 12 years of age and older who are severely immunocompromised, based on published literature data; the Package Leaflet is updated accordingly." Opinion adopted on 04.10.2021.	Positive Opinion adopted by consensus on 04.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. See 9.1
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0067 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to introduce a booster dose (third dose) of Comirnaty for individuals 18 years of age and older, based on interim safety and immunogenicity data from	Positive Opinion adopted by consensus on 04.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. See 9.1

the interventional study C4591001, " A Phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals". The package leaflet is updated accordingly." Opinion adopted on 04.10.2021.	
Darzalex - daratumumab - EMEA/H/C/004077/II/0050, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 4.8 of the SmPC in order to add hypogammaglobulinemia to the list of adverse drug reactions (ADRs) with frequency common, based on new information and previously reviewed pooled safety data from Part 2 of Phase 3 Clinical Study 54767414MMY3006 comparing daratumumab versus observation as maintenance in patients with newly diagnosed Multiple Myeloma who are post-ASCT transplant. The Package Leaflet is updated accordingly." Opinion adopted on 07.10.2021. Request for Supplementary Information adopted on 02.09.2021.	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Darzalex - daratumumab - EMEA/H/C/004077/II/0051/G, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 5.1 of the SmPC in order to update PFS and OS data based on interim results from study MMY3006 (CCO 27/8/2020); this is a Phase 3, randomized, open-label, parallel-group, active-control, multicenter study of daratumumab combined with VTd for NDMM patients eligible for ASCT. This fulfils a post-approval commitment of procedure EMEA/H/C/004077//II/0030 to provide updated Part 1 PFS and OS data, with censoring the patients randomized to daratumumab in Part 2 of this study. C.I.4 Update of section 5.1 of the SmPC of DARZALEX SC formulation to provide the mature OS data based on final results from study MMY3012 (CCO 04/11/2020); this is a Phase 3, multicenter, randomized, open-label, active-controlled study to demonstrate that the	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

efficacy and PK for daratumumab SC are not inferior to those for daratumumab IV in subjects with RRMM submitted for the approval of the SC formulation in procedure EMEA/H/C/004077//II/0032" Opinion adopted on 07.10.2021. Request for Supplementary Information adopted on 02.09.2021.	
Darzalex - daratumumab - EMEA/H/C/004077/II/0053, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 5.1 of the SmPC in order to update PFS and OS (CCO 19/2/2021) data based on interim results from study MMY3008; This is a Phase 3, randomized, open-label, active controlled, parallel-group, multicenter study in adults with newly diagnosed MM not eligible for ASCT comparing DRd vs Rd. The Marketing authorisation holder (MAH) took the opportunity to make minor formatting and linguistic changes in the PI." Request for Supplementary Information adopted on 07.10.2021, 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Drovelis - drospirenone / estetrol - EMEA/H/C/005336/II/0002 Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.), Rapporteur: Kristina Dunder, "Update of section 5.3 of the SmPC following a revision of the Environmental Risk Assessment (ERA) in order to include the E4 PECsw based on a refined Fpen of 0.0044. In addition, the MAH has taken the opportunity to implement minor editorial changes in the SmPC, Labelling and Package Leaflet." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Dupixent - dupilumab - EMEA/H/C/004390/II/0046 sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, "Update of section 4.8 of the SmPC to introduce a new ADR (facial rash) with uncommon frequency. The package leaflet will be updated accordingly." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 08.07.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Entyvio - vedolizumab -	Positive Opinion adopted by consensus on

EMEA/H/C/002782/II/0059/G Takeda Pharma A/S, Rapporteur: Armando Genazzani, "C.I.4 Update of section 4.6 of the Summary of Products Characteristics (SmPC) in order to implement information on lactation based on study Vedolizumab-4001 (An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically). The study aimed to determine the PK parameters of vedolizumab in breast milk and to estimate mean daily infant dosage over the dosing interval through breast milk, and percentage of maternal dose consumed in breast milk by the infants. C.I.4 Update of section 5.2 of the SmPC in order to adjust the values for clearance and serum half-life of vedolizumab IV and SC in subjects with ulcerative colitis and Crohn's disease. The updated pop PK dataset consists of pooled data across 4 phase 3 studies (C13006, C13007, MLN0002SC-3027, MLN0002SC-3031) and 1 open-label extension study (MLN0002SC-3030). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to correct minor typographical errors and to bring the PI in line with the latest QRD template version 10.2 rev. 1." Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 02.09.2021, 10.06.2021.	14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Erleada - apalutamide - EMEA/H/C/004452/II/0015 Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "An updated OS analysis was conducted at the time of final study analysis when 405 deaths were observed with a median follow-up of 44 months. Results from this updated analysis were consistent with those from the pre specified interim analysis. The improvement in OS was demonstrated even though 39% of patients in the placebo arm crossed over to receive Erleada, with a median treatment of 15 months on Erleada crossover. Consistent improvement in OS was observed across patient subgroups including high- or low-	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

volume disease, metastasis stage at diagnosis (M0 or M1), and Gleason score at diagnosis (≤7 vs. >7)." Opinion adopted on 07.10.2021. Request for Supplementary Information adopted on 02.09.2021, 08.07.2021.	
Erleada - apalutamide - EMEA/H/C/004452/II/0016 Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of section 4.8 of the SmPC in order to add Stevens-Johnson Syndrome (SJS) to the list of adverse drug reactions (ADRs) with frequency not known. Cases of SJS were observed in post-marketing data. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 14.10.2021, 02.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Fasenra - benralizumab - EMEA/H/C/004433/II/0036** AstraZeneca AB, Rapporteur: Fátima Ventura, PRAC Rapporteur: David Olsen, PRAC-CHMP liaison: Ingrid Wang, "Update of RMP to remove long-term use of benralizumab, serious hypersensibility, loss/reduction of long-term efficacy due to persistent neutralising anti-drug antibodies as safety concerns and to change categorisation of helminth infection from important identified risk to important potential risk. RMP version 4.1 is accepted." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 08.07.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Iclusig - ponatinib - EMEA/H/C/002695/II/0061, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on results from the OPTIC study (AP24534-14-203) listed as a specific obligation in the Annex II. This is a randomised, open-label, Phase 2 trial of ponatinib in patients with chronic myeloid leukemia to characterise the efficacy and safety of ponatinib over a range of doses; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 14.10.2021.	
Invokana - canagliflozin - EMEA/H/C/002649/II/0055 Janssen-Cilag International NV, Rapporteur: Martina Weise, "Update of sections 4.2, 4.4 and 5.1 of the SmPC to amend posology information concerning the treatment of patients with eGFR between ≥30 and <45 mL/min/1.73 m2, whether or not albuminuria is present, based on further analysis of previously submitted CANVAS data (studies DIA3008 and DIA4003). The Applicant has also taken the opportunity to make minor editorial changes to SmPC section 4.5." Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 22.04.2021, 28.01.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. See 9.1
Ivemend - fosaprepitant - EMEA/H/C/000743/II/0045 Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC with the final results from study P045; a non-randomised, single-group, multi-site, open-label study to evaluate the safety and tolerability of consecutive 3-day intravenous fosaprepitant in paediatric participants scheduled to receive a moderately or highly emetogenic chemotherapy agent/regimen or a chemotherapy agent/regimen not previously tolerated due to vomiting. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and correct the date of the latest renewal in section 9 of the SmPC." Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Lydisilka - drospirenone / estetrol - EMEA/H/C/005382/II/0002 Estetra SRL, Duplicate, Duplicate of Drovelis, Rapporteur: Kristina Dunder, "Update of section 5.3 of the SmPC following a revision of the Environmental Risk Assessment (ERA) in order to include the E4 PECsw based on a refined Fpen of 0.0044. In addition, the MAH has taken the opportunity to implement minor editorial changes in the SmPC, the Labelling and Package Leaflet." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Mayzent - siponimod -	Request for supplementary information adopted

EMEA/H/C/004712/II/0011/G Novartis Europharm Limited, Rapporteur: Kirstine Moll Harboe, "- Update of sections 4.4 and 4.5 of the SmPC to add information in case of administration of non-live attenuated vaccines, based on the vaccination study A2130. - Update of section 4.5 of the SmPC to clarify the CYP2C9/CYP3A4 inhibitors/inducers information. - Update of section 5.2 to add information regarding CYP2C9 genotypes less frequent alleles." Request for Supplementary Information adopted on 23.09.2021.	with a specific timetable.
Mektovi - binimetinib - EMEA/H/C/004579/II/0015 Pierre Fabre Medicament, Rapporteur: Janet Koenig, "Submission of the final results from Arm 2 of study ARRAY-818-103. This is a Phase 1, three-arm, open-label drug-drug interaction study in patients with BRAF V600-mutant unresectable or metastatic melanoma or other BRAF V600-E and/or K-mutant advanced solid tumours." Opinion adopted on 14.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0050 Orexigen Therapeutics Ireland Limited, Rapporteur: Kirstine Moll Harboe, "Submission of the final report of study 20077697; a Toxicity Study of Bupropion and Naltrexone by Twice Daily Oral (Gavage) in Juvenile Mice." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
Noxafil - posaconazole - EMEA/H/C/000610/II/0067 Merck Sharp & Dohme B.V., Rapporteur: Alexandre Moreau, "Update of sections 4.4 and 4.5 of the SmPC in order to add drug-drug interaction information between posaconazole and venetoclax. The Package leaflet is updated accordingly." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
Nuceiva - botulinum toxin type A - EMEA/H/C/004587/II/0017 Evolus Pharma Limited, Rapporteur: Peter Kiely,	Request for supplementary information adopted with a specific timetable.

"Submission of the final reports of the non-interventional immunogenicity analysis (RMP cat 3 study)." Request for Supplementary Information adopted on 23.09.2021.	
Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/II/0075 Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, "Update of sections 4.1, 4.2, 4.4, 5.1, 5.2 and 6.6 of the SmPC in order to revise the definition of severe LH and FSH deficiency and to clarify the treatment target and the pharmacokinetic and pharmacodynamic properties of the two gonadotropins included in the medicinal product, as well as disposal precautions, based on current medical guidelines, clinical practice and literature; the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2 and to align with the guideline on the Excipients in the labelling and package leaflet of the medicinal products for human use." Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 02.09.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386/II/0007 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of the immunogenicity information in section 4.8 of the SmPC based on the analysis of the Federica study (Phase III clinical trial in patients with HER2 overexpressing early breast cancer)." Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
ProQuad - measles, mumps, rubella and varicella vaccine (live) - EMEA/H/C/000622/II/0151/G MSD Vaccins, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC to remove adverse events with no biological plausible cause in response to an EMA comment received during procedure EMEA/H/C/000622/WS1392. In addition, the MAH proposed amendments to other aspects of SmPC section 4.8 to minimise redundancies and update outdated terms to the current version of the Medical Dictionary for Regulatory Activities	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

(MedDRA). The Package Leaflet is updated accordingly. Update of section 4.9 of the SmPC to revise the information on overdose following review of MAH`s safety database search for ProQuad. In addition, the MAH took the opportunity to update the contact details for the local representatives in the Package Leaflet." Opinion adopted on 30.09.2021.	
Revestive - teduglutide - EMEA/H/C/002345/II/0053, Orphan Shire Pharmaceuticals Ireland Limited, Rapporteur: Kirstine Moll Harboe, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the Product information with results from two studies included in the paediatric investigation plan (PIP). Study SHP633-1 was performed to evaluate the safety, efficacy/pharmacodynamics (PD), and pharmacokinetics (PK) of teduglutide in infants 4 to 12 months gestational age with SBS and who are dependent on parenteral support. The second study is a paediatric population PK model including data from study SHP633-301. The Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to make editorial changes to section 4.5 of the SmPC." Request for Supplementary Information adopted on 14.10.2021, 24.06.2021.	Request for supplementary information adopted with a specific timetable.
SIRTURO - bedaquiline - EMEA/H/C/002614/II/0043, Orphan Janssen-Cilag International NV, Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC to revise the information on the use of bedaquiline in combination with other medicinal products and to amend the information regarding treatment duration. In addition, the MAH took the opportunity to include an editorial correction in section 5.1 of the SmPC and to update the contact details for the local representative for UK in the package leaflet, in line with QRD version 10.2." Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 22.07.2021, 24.06.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Spikevax - covid-19 mrna vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0031	Positive Opinion adopted by consensus on 04.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.2 and 4.4 of the SmPC in order to introduce a third dose of Spikevax in the primary vaccination schedule for individuals 12 years of age and older who are severely immunocompromised, based on published literature data; the Package Leaflet is updated accordingly. The MAH took the opportunity to make minor administrative and editorial corrections throughout the product information." Opinion adopted on 04.10.2021.	recommendation. See 9.1
Talzenna - talazoparib - EMEA/H/C/004674/II/0010/G Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, "Update of section 4.4 of the SmPC in order to update the frequency of myelodysplastic syndrome/acute myeloid syndrome (MDS/AML) based on a cumulative safety review; Update of section 5.1 of the SmPC with the revised ATC code. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and make minor corrections in the SmPC and PL." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
Tivicay - dolutegravir - EMEA/H/C/002753/II/0073/G ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 5.1 of the Tivicay SmPC in order to add new information on efficacy and safety based on data from studies 204861 (GEMINI-1) and 205543 (GEMINI-2). These are Phase III, identical, ongoing, randomized, double-blind, parallel group studies, to provide longer term efficacy and safety data on the use of dolutegravir (DTG) for the treatment of HIV-1 infection. The Package Leaflet is updated accordingly. The grouping includes a Type IA variation to update the ATC code for both Film Coated and Dispersible Tablets. In addition, the MAH took the opportunity to include an editorial correction to the list of excipients in the SmPC and Package Leaflet and to update the list of local representatives in the Package Leaflet." Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Toviaz - fesoterodine - EMEA/H/C/000723/II/0063 Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, "C.I.3 Update of sections 4.2, 5.1 and 5.2 of the SmPC with the results from study A0221047, to evaluate the safety and efficacy of fesoterodine in subjects aged 6 to 17 years with neurogenic detrusor overactivity. The change was suggested in the outcome of the EMEA/H/C/000723/P46/030.1. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1." Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0031 AstraZeneca AB, Rapporteur: Sol Ruiz, "Submission of the final study report for MS1222-0002 "In Vitro Assay to Determine Release of Spike Protein From Transduced Cells" to fulfil the imposed study as reflected in Annex II of the product information and the RMP. As a result, Annex II of the product information is being updated to remove this study. The MAH is taking the opportunity to provide two additional studies linked to support the investigation on the platelet activation: the final study report for MS1222-0001 "Computational Prediction of Spike Protein Interaction with Platelet Factor 4 (PF4)" which is the first report requested within the required studies for "in vitro interaction of AZD1222 or spike protein with PF4 and/or platelets" as reflected in the RMP; and the study report for 520447 "Investigative Vaccine Study in the Mouse" to evaluate spike protein levels and haematology parameters." Request for Supplementary Information adopted on 23.09.2021.	Request for supplementary information adopted with a specific timetable.
Veklury - remdesivir - EMEA/H/C/005622/II/0025/G Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of section 5.1 of the SmPC with nonclinical results following final study reports	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

addressing the activity of remdesivir in additional cell lines and chloroquine/hydroxychloroquine antagonism (fulfilment of 3 components of the Specific Obligation SOB 012 from EMEA/H/C/005622/R/0015). In addition, the Marketing authorisation holder (MAH) took the opportunity to submit the interim results of the non-clinical studies related to the characterisation of clinical isolates and/or recombinant viruses with P323L, A97V and A547V substitutions." Opinion adopted on 14.10.2021.	
Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/II/0032 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to add new information on efficacy and safety based on final results from study GS-US-320-4035. This was a phase 2, open-label study to evaluate the safety and efficacy of switching to tenofovir alafenamide from tenofovir disoproxil fumarate and/or other oral antiviral treatment in virologically suppressed chronic hepatitis B subjects with renal and/or hepatic impairment." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 10.06.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Venclyxto - venetoclax - EMEA/H/C/004106/II/0035 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "Submission of the final report from study M12-175 listed as a category 3 study in the RMP. This is a Phase 1 study evaluating the safety and pharmacokinetics of venetoclax in subjects with relapsed or refractory Chronic Lymphocytic Leukaemia and Non-Hodgkin's Lymphoma." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Venclyxto - venetoclax - EMEA/H/C/004106/II/0036 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "Submission of the final report from study M13-982 listed as a category 3 study in the RMP. This is a phase 2 open-label study of the efficacy of ABT-199 in subjects with relapsed or refractory Chronic	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Lymphocytic Leukaemia Harboring the 17p Deletion." Opinion adopted on 30.09.2021.	
Vocabria - cabotegravir - EMEA/H/C/004976/II/0007 ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC in order to update the adverse reactions section, adding information regarding events of pyrexia have a close temporal association with injections. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to include minor typographical updates." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Votrient - pazopanib - EMEA/H/C/001141/II/0068 Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, "Update of section 4.8 of the SmPC in order to add skin ulcer to the list of adverse drug reactions (ADRs) with frequency of "uncommon" and to update the frequency of the ADR aneurysm from "not known" to "rare". Further editorial changes and a simplification in the presentation of the frequencies of ADRs in section 4.8 are being proposed. The Package Leaflet is updated accordingly." Opinion adopted on 07.10.2021.	Positive Opinion adopted by consensus on 07.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Xyrem - sodium oxybate - EMEA/H/C/000593/II/0093 UCB Pharma S.A., Rapporteur: Bruno Sepodes, "Update of section 4.9 of the SmPC in order to add a new warning on acidosis and its management following the assessment of the signal 'metabolic acidosis' triggered by routine literature review. In addition, the MAH took the opportunity to implement a minor editorial change in section 4.8 of the SmPC, to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.2." Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Zeffix - lamivudine - EMEA/H/C/000242/II/0082 GlaxoSmithKline (Ireland) Limited, Duplicate, Duplicate of Epivir, Rapporteur: Jean-Michel Race, "Update of section 5.2 of the SmPC in order to update pharmacokinetic information	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

based on results from bioavailability studies (204993 and 204994) with lamivudine-containing products." Opinion adopted on 23.09.2021.	
Zeffix - lamivudine - EMEA/H/C/000242/II/0083 GlaxoSmithKline (Ireland) Limited, Duplicate, Duplicate of Epivir, Rapporteur: Jean-Michel Race, "Update of section 4.9 of the SmPC in order to update the Overdosage of the GDS for lamivudine-human immunodeficiency virus (HIV) information based on the safety database. The section 3 of the package leaflet is updated accordingly." Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1874/G **Advagraf-EMEA/H/C/000712/WS1874/0058/G** **Modigraf-EMEA/H/C/000954/WS1874/0036/G** Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, "C.I.4 - Update of sections 4.4 and 4.5 of the SmPC on the drug-drug interaction with CYP3A4 based on a comprehensive review of available data. Section 4.5 of the SmPC is also updated to include impact of direct acting antiviral therapy. C.I.z - Update of section 4.8 of the SmPC to add posterior reversible encephalopathy syndrome as an adverse reaction. The MAH took also the opportunity to change the SOC for febrile neutropenia from General disorders and administration site conditions to Blood and lymphatic system disorders in section 4.8 of the SmPC and to update the instruction for handling of the product in section 6.6 of the SmPC. The Package Leaflet is updated accordingly." Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 24.06.2021, 25.02.2021, 17.09.2020.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2048 **Kalydeco-EMEA/H/C/002494/WS2048/0101** **Symkevi-EMEA/H/C/004682/WS2048/0030** Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Rhea Fitzgerald, "Update of the Product information to provide the final	Request for supplementary information adopted with a specific timetable.

clinical study report (CSR) Part A of study VX17-661-116 (A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation). Consequently, the SmPC sections 4.2, 4.5, 4.8 and 5.1 and the package leaflet are updated accordingly. The RMP is also updated." Request for Supplementary Information adopted on 14.10.2021, 24.06.2021.	
WS2085 **Kaftrio-EMEA/H/C/005269/WS2085/0014** **Kalydeco-EMEA/H/C/002494/WS2085/0099** Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Martin Huber, "Update of sections 4.4 and 4.8 of the Summary of Product Characteristics (SmPC) to add "liver injury" and "total bilirubin elevations" as new adverse reactions with a frequency unknown and reinforce corresponding existing warning following cases of liver injury and liver failure in the post marketing setting. The Package Leaflet (PL) is updated accordingly. Kaftrio's RMP is updated to version 3.1 to upgrade hepatoxicity from a potentially serious risk to an important identified risk." Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 16.09.2021, 24.06.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.3. CHMP-PRAC assessed procedures

ADCETRIS - brentuximab vedotin - EMEA/H/C/002455/II/0093, Orphan Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC based on results from study C25004, an open-label study in order to assess the safety and tolerability, of brentuximab vedotin when combined with multiagent chemotherapy regimen for first-line treatment of advanced-stage Hodgkin lymphoma in paediatric patients. The RMP	Request for supplementary information adopted with a specific timetable.

version 16 has also been submitted." Request for Supplementary Information adopted on 30.09.2021.	
Adenuric - febuxostat - EMEA/H/C/000777/II/0061 Menarini International Operations Luxembourg S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser, "C.I.4 - Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study FAST (Febuxostat versus Allopurinol Streamlined Trial) listed as a category 3 study in the RMP; this is an interventional study investigating the cardiovascular safety of febuxostat in comparison with allopurinol in patients with chronic symptomatic hyperuricaemia. The Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to update the warning relevant to the content of sodium according to the Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use'." Request for Supplementary Information adopted on 14.10.2021, 24.06.2021.	Request for supplementary information adopted with a specific timetable.
Alunbrig - brigatinib / brigatinib - EMEA/H/C/004248/II/0037 Takeda Pharma A/S, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study AP26113-13-301 listed as a PAES in the Annex II; this is a randomised, open-label, multicentre phase III study comparing brigatinib versus crizotinib in patients with advanced ALK-positive NSCLC who have not previously received ALK-directed therapy; The RMP version 5.4 has also been submitted." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0018 Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla	Request for supplementary information adopted with a specific timetable.

Wändel Liminga, "Submission of an updated RMP version 2.2 in order to include the following: • To include thrombocytopenia as an important potential risk following the outcome of the signal of Embolic and Thrombotic events (SDA 018.1, EPITT number 19689) and the opinion of procedure EMEA/H/C/005737/II/0006/G • To propose studies aimed at further characterisation of Thrombosis with Thrombocytopenia syndrome (TTS) and thrombocytopenia, following the outcome of the signal of Embolic and Thrombotic events (SDA 018.1, EPITT number 19689) • To include Guillain-Barré syndrome as an important identified risk and update the RMP accordingly (EMEA/H/C/005737/II/0012). In addition, the MAH took the opportunity to update in the EU-RMP the submission milestone dates for VAC31518COV4001 and VAC31518COV4002 studies." Request for Supplementary Information adopted on 30.09.2021.	
Galafold - migalastat - EMEA/H/C/004059/II/0034, Orphan Amicus Therapeutics Europe Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga, "To update sections 4.8, 5.1 and 5.2 of the SmPC based on final results from study AT1001-020 listed as category 3 in the RMP. Study AT1001-020-is a Phase 3b, 2-stage, open-label, uncontrolled, multicenter study to evaluate the safety, pharmacokinetic, pharmacodynamic and efficacy of migalastat treatment in paediatric subjects 12 to < 18 years of age and weighing ≥ 45 kg with Fabry disease and with amenable GLA variants. The updated RMP version 7.0 has also been submitted. The final results of study AT1001-020, which is involving paediatric patients are submitted in fulfilment of Article 46 of Regulation 1901/2006, as amended. In addition, the MAH took the opportunity to introduce some minor editorial changes to the SmPC and Package Leaflet and bring the PI in line with the latest QRD template v. 10.2." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 30.09.2021.	
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0068, Orphan Janssen-Cilag International NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of section 4.4 of the SmPC in order to add baseline monitoring in addition to the current warnings for periodic monitoring of cardiac failure and cardiac arrhythmias in patients receiving ibrutinib. The Package Leaflet is updated accordingly. The RMP version 18.1 has also been submitted." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
TOOKAD - padeliporfin - EMEA/H/C/004182/II/0015 STEBA Biotech S.A, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maia Uusküla, "C.I.11.b - Submission of the Clinical Study Report for category 1 study: Post-authorisation efficacy study (PAES): CLIN1001 PCM301FU5, A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD Soluble for Localised Prostate Cancer compared to Active Surveillance. The Annex 2 has been updated to remove reference to this study." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
Tremfya - guselkumab - EMEA/H/C/004271/II/0028 Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.8 and 5.1 of the SmPC in order to revise the safety and efficacy profile in the EU product information based on 5 years data from the final study reports of pivotal psoriasis studies PSO3001 and PSO3002 listed as additional PV activities (category 3 studies) in the RMP; these are randomized, double-blind, multicenter, placebo- and active comparator-controlled studies through 48 weeks of treatment. In the long-term extension part of these studies subjects received open-label guselkumab q8w, starting at Week 52 in PSO3001 and at Week 76 in PSO3002, with the last dose at Week 252 and the last safety follow-up visit at Week 264. The RMP version 8.1 is accepted. In addition, the MAH took the opportunity to update the list of	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

local representatives in the Package Leaflet." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 02.09.2021, 10.06.2021.	
Trogarzo - ibalizumab - EMEA/H/C/004961/II/0015 Theratechnologies Europe Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: David Olsen, "Submission of an updated RMP version 2.0 in order to reflect the new timelines of the PROMISE study and to align the information included in the RMP with the latest PSUR. As the PROMISE study is a condition of the Trogarzo marketing authorisation, the delayed start date results in a change to Annex II of the marketing authorisation. The date for providing the final study report is changing ." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
Ultomiris - ravulizumab - EMEA/H/C/004954/II/0016 Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola, "to update section 4.4 Special warnings and precautions for use and section 4.8 Undesirable effects of the SmPC, with consequential updates to sections 2 and 4 of the Patient Information Leaflet regarding anaphylactic reaction, hypersensitivity and infusion-related reactions." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 08.07.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0026 AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to include updated efficacy and safety information based on primary analysis from study D8110C00001 listed as a specific obligation in Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicenter study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria; the Package Leaflet and Annex II are updated accordingly. The updated RMP Version 3 Succession 4 is approved." Opinion adopted on 14.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. See 9.1

Request for Supplementary Information adopted on 16.09.2021, 22.07.2021.	

B.5.4. PRAC assessed procedures

PRAC Led **AUBAGIO - teriflunomide - EMEA/H/C/002514/II/0038** sanofi-aventis groupe, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final PASS OBS12753 study report listed as a category 3 study in the RMP. This is a prospective cohort study of long-term safety of teriflunomide in multiple sclerosis patients in Europe. The updated RMP v 7.1 is proposed." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Beovu - brolucizumab - EMEA/H/C/004913/II/0008** Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of section 4.4 of the SmPC with a subsection on intraocular inflammation and update of the warning on intraocular inflammation including retinal vasculitis and/or retinal vascular occlusion, and update of section 4.8 of the SmPC to update the frequency of the ADRs "Retinal vasculitis" and "Retinal vascular occlusion" to "uncommon"; to merge "Retinal artery occlusion" and "retinal vascular occlusion" into "retinal vascular occlusion"; and to update the description of immunogenicity. All of this is based on the final results of 2 retrospective real-world studies that evaluated patients with nAMD for up to 6 months after initiating treatment with brolucizumab and a mechanistic study BASICHR0049 that identified an immune cause of intraocular inflammation including retinal vasculitis and retinal vascular occlusion. The Package Leaflet is updated accordingly. The updated RMP version 7.0 has also been submitted. Furthermore, the CHMP considers that this variation implements changes to the decision	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

granting the marketing authorisation due to a significant public health concern." Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 10.06.2021.	
PRAC Led **COMIRNATY - tozinameran - EMEA/H/C/005735/II/0059** BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP for COMIRNATY version 2.3 in order to add myocarditis/pericarditis as an important identified risk as per PRAC outcome EMEA/H/C/005735/SDA/032, dated 08. July 2021 (EPITT: 19712)]. This includes update of the risk minimisation measures related to myocarditis/pericarditis. The MAH is taking the opportunity to update the RMP in line with exposure data at DLP 18 June 2021, the information on planned/ongoing safety studies (protocols C4591011 [US], C4591012 [US], and C4591021 [EU]) and inclusion of two new non-interventional US PASS: C4591009 and Paediatric Heart Network." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0020** Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, " Update of sections 4.4 and 4.8 of the SmPC to add a new warning on immune thrombocytopenia (ITP), and to add dizziness and ITP to the list of adverse drug reactions with frequencies uncommon and not known, respectively; based on the PRAC request from the post-authorisation measure MEA/014.3 (4th Monthly Summary Safety Report covering the month of June 2021). The package leaflet is updated accordingly. A DHPC and communication plan was adopted." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Fotivda - tivozanib -**	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP

EMEA/H/C/004131/II/0018 EUSA Pharma (Netherlands) B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Rugile Pilviniene, PRAC-CHMP liaison: Romaldas Mačiulaitis, "Submission of an updated RMP version 4.0 in order to include data from the phase III study TIVO-3, a randomised, controlled, multi-centre, open-label study to compare tivozanib with sorafenib in subjects with advanced Renal Cell Carcinoma. Additional updates to the RMP include new information from clinical studies and post-marketing exposure." Opinion adopted on 30.09.2021.	Members were in agreement with the CHMP recommendation.
PRAC Led **Inflectra - infliximab - EMEA/H/C/002778/II/0100/G** Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of the final CSRs for CT-P13 registry studies in Inflammatory Bowel Disease (IBD), Ankylosing Spondylitis (AS) and Rheumatoid Arthritis (RA) initiated with the objective of assessing long-term safety in these indications: • Final report for CT-P13 4.3 (EU and Korean IBD Registry; one study for Remsima and one study for Inflectra) • Final report for CT-P13 4.4 (EU and Korean AS Registry; one study for Remsima and one study for Inflectra) • Final report for BSRBR-RA Registry (one study equally applicable to Remsima and Inflectra) • Final report for RABBIT Registry (one study equally applicable to Remsima and Inflectra)" Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Mavenclad - cladribine - EMEA/H/C/004230/II/0015** Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "Submission of an updated RMP version 1.5.2 in order to bring it in line with the RMP template Rev. 2.0.1. In addition, the MAH took the opportunity to include long-term safety data from the completed PREMIERE registry: a prospective observational long-term safety	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

registry of multiple sclerosis patients who have participated in cladribine clinical studies; and to remove it from the pharmacovigilance plan. Furthermore, the status of the post-approval safety studies MS 700568-0002: a long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis newly started on oral cladribine (CLARION); and MS 700568-0004: pregnancy outcomes in women exposed to oral cladribine: a multi-country cohort database study (CLEAR) are updated. Finally, the RMP is updated in line with the conclusions of the PSUSA procedure (PSUSA/00010634/201907)." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 10.06.2021, 06.05.2021, 14.01.2021.	
PRAC Led **Nivestim - filgrastim - EMEA/H/C/001142/II/0063** Pfizer Europe MA EEIG, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of an updated RMP version 10.1 in order to update the RMP in accordance with GVP Module V and the Guidance on the format of the RMP in the EU - in integrated format (Rev. 2.0.1) and to propose deletion of selected safety concerns listed as important identified risk, important potential risk and missing information." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **OCALIVA - obeticholic acid - EMEA/H/C/004093/II/0026, Orphan** Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of the RMP to version 1.3 (dated of 11 June 2021) in order to update the format in accordance with template to EMA/164014/2018 Rev.2.0.1 and to add Specific Obligation clinical studies 747-302 and 747-401 to part IV. Plans for post-authorisation efficacy studies of the RMP. This change has been agreed by the CHMP in the outcome Ocaliva 2020 Annual Renewal (EMEA/H/C/004093/R/0023). Other changes also include an update to the	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

exposure data from clinical studies and addition of data on post-marketing experience up to the DLP (26 May 2020) and addition of some specific relevant SmPC wording in the risk minimisation measures." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 06.05.2021.	
PRAC Led **Otezla - apremilast - EMEA/H/C/003746/II/0038** Amgen Europe B.V., Rapporteur: Peter Kiely, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13 - Submission of the final study report (CSR) from PsOBest Registry, listed as a category 3 study in the RMP. This is an observational study to assess the long-term safety and effectiveness of apremilast in routine clinical practice in Germany. The RMP version 14.0 has also been submitted." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Otezla - apremilast - EMEA/H/C/003746/II/0039** Amgen Europe B.V., Rapporteur: Peter Kiely, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13- Submission of the final study report (CSR) from UK Clinical Practice Research Database (CPRD), listed as a category 3 study in the RMP. This is an observational study to assess the long-term data of apremilast in patients with psoriasis and psoriatic arthritis. The RMP version 14.0 has also been submitted." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Pradaxa - dabigatran etexilate - EMEA/H/C/000829/II/0126/G** Boehringer Ingelheim International GmbH, Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Kirstine Moll Harboe, "C.I.13: Submission of the final report from drug utilisation study, 1160.129, GLORIA AF. This is a three-phase, international, multicenter, prospective, observational registry program in	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

patients with newly diagnosed non-valvular atrial fibrillation (NV AF) at risk for stroke. The objective of the registry program is to investigate patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in NV AF patients globally and to collect data from clinical practice settings on important outcome events of antithrombotic treatments for the prevention of stroke. C.I.13: Submission of the final report from drug utilisation study, 1160.136, EU GLORIA AF listed as a category 3 study in the RMP. This is a three-phase, international, multicenter, prospective, observational registry program in patients with newly diagnosed non-valvular atrial fibrillation (NV AF) at risk for stroke. The objective of the registry program is to investigate patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in NV AF patients from participating countries in EU/EEA Member States and to collect data from clinical practice settings on important outcome events of antithrombotic treatments for the prevention of stroke. The RMP version 39 has also been submitted." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 10.06.2021.	
PRAC Led **Remsima - infliximab - EMEA/H/C/002576/II/0103/G** Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of the final CSRs for CT-P13 registry studies in IBD, AS and RA initiated with the objective of assessing long-term safety in these indications: • Final report for CT-P13 4.3 (EU and Korean IBD Registry) • Final report for CT-P13 4.4 (EU and Korean AS Registry) • Final report for BSRBR-RA Registry • Final report for RABBIT Registry" Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/II/0024** sanofi-aventis groupe, Rapporteur: Kristina	Request for supplementary information adopted with a specific timetable.

Dunder, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final Clinical Study Report of the category 3 PASS INSLIC08571, a 'Survey to evaluate the knowledge and understanding of the key safety messages in the healthcare professional guide and the patient guide'. The provision of the final survey results addresses post-authorisation measure (PAM) MEA 002. The updated RMP version 6.0 has also been submitted." Request for Supplementary Information adopted on 30.09.2021.	
PRAC Led **Truvada - emtricitabine / tenofovir disoproxil - EMEA/H/C/000594/II/0173** Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Removal of the additional risk minimisation measures (aRMMs) for the PrEP indication risks, from the Truvada EU RMP and Annex II of the Truvada PI. With this variation, version 17.2 of the RMP (dated 1st July 2021) is submitted." Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS1970** **Eucreas-EMEA/H/C/000807/WS1970/0081** **Galvus-EMEA/H/C/000771/WS1970/0067** **Icandra-EMEA/H/C/001050/WS1970/0084** **Jalra-EMEA/H/C/001048/WS1970/0069** **Xiliarx-EMEA/H/C/001051/WS1970/0067** **Zomarist-EMEA/H/C/001049/WS1970/0083** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP (version 15.2) in order to bring it in line with revision 2 of GVP module V on 'Risk management systems' and aligned with the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00003113/201802) adopted in October 2018. Annex II.D of the product information is updated to remove the statement around	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

submission of an RMP update every 3 years." Opinion adopted on 30.09.2021. Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.	
PRAC Led **WS2050/G** **Corlentor-EMEA/H/C/000598/WS2050/0056/G** **Procoralan-EMEA/H/C/000597/WS2050/0055/G** Les Laboratoires Servier, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To update the RMP for Procoralan and Corlentor following the assessment for the same changes approved for Ivabradine Anpharm EMEA/H/C/4187/R/014. In addition, the PI also has been updated following EMA QRD review following the same assessment. The MAH has finally also introduced changes related to QRD 10.2 in section 6 of the PL." Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **WS2078** **Lixiana-EMEA/H/C/002629/WS2078/0034** **Roteas-EMEA/H/C/004339/WS2078/0020** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "C.I.13: Submission of the final report from study ETNA-VTE-EUROPE (DSE-EDO-05-14-EU), listed as a category 3 study in the RMP. This is a Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients with Venous Thromboembolism in Europe. The RMP version 12.0 has also been submitted." Request for Supplementary Information adopted on 14.10.2021.	Request for supplementary information adopted with a specific timetable.

B.5.5. CHMP-CAT assessed procedures

Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0046, ATMP Amgen Europe B.V., Rapporteur: Heli Suila, CHMP Coordinator: Johanna Lähteenvuo, "Submission to provide preliminary efficacy	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

results from the phase III part of the study 20110265 to fulfil the obligation listed in the Annex II of the Product Information. The concerned study is a Phase 1b/3, multicenter trial of talimogene laherparepvec in combination with pembrolizumab compared with placebo in combination with pembrolizumab for treatment of unresectable stage IIIB to IVM1c melanoma. The Annex II is updated accordingly." Opinion adopted on 14.10.2021, 08.10.2021.	
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0040, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Johanna Lähteenvuo Opinion adopted on 14.10.2021, 08.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Libmeldy - atidarsagene autotemcel - EMEA/H/C/005321/II/0004, Orphan, ATMP Orchard Therapeutics (Netherlands) BV, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege Request for Supplementary Information adopted on 08.10.2021.	Request for supplementary information adopted with a specific timetable.
Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - EMEA/H/C/005102/II/0012, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 08.10.2021.	Request for supplementary information adopted with a specific timetable.
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0015, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege, "Updates to sections 4.4, 4.8 and 5.1 of the SmPC to reflect the final study results AVXS-101-CL-302; a Post-authorisation efficacy study intended to confirm the efficacy and safety and tolerability of a single dose of Zolgensma in patients younger than 6 months	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

of age with SMA Type 1 with One or Two SMN2 Copies. The package leaflet has been updated accordingly and annex II has been updated to reflect completion of this Specific Obligation." Opinion adopted on 14.10.2021, 08.10.2021. Request for Supplementary Information adopted on 16.07.2021.	
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0017/G, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege Opinion adopted on 14.10.2021, 08.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2088/G **Brimica Genuair-EMEA/H/C/003969/ WS2088/0033/G** **Duaklir Genuair-EMEA/H/C/003745/ WS2088/0033/G** AstraZeneca AB, Lead Rapporteur: Ewa Balkowiec Iskra Request for Supplementary Information adopted on 23.09.2021.	Request for supplementary information adopted with a specific timetable.
WS2099 **HyQvia-EMEA/H/C/002491/WS2099/0073** **Kiovig-EMEA/H/C/000628/WS2099/0111** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 14.10.2021. Request for Supplementary Information adopted on 02.09.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2103 **Enurev Breezhaler-EMEA/H/C/002691/ WS2103/0038** **Seebri Breezhaler-EMEA/H/C/002430/ WS2103/0038** **Tovanor Breezhaler-EMEA/H/C/002690/ WS2103/0042** **Ultibro Breezhaler-EMEA/H/C/002679/**	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS2103/0040 **Ulunar Breezhaler-EMEA/H/C/003875/ WS2103/0041** **Xoterna Breezhaler-EMEA/H/C/003755/ WS2103/0044** Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe, Opinion adopted on 30.09.2021.	
WS2105/G **Corbilta-EMEA/H/C/002785/WS2105/ 0025/G** **Levodopa/Carbidopa/Entacapone Orion-EMEA/H/C/002441/WS2105/0033/G** **Stalevo-EMEA/H/C/000511/WS2105/ 0095/G** Orion Corporation, Lead Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 30.09.2021.	Request for supplementary information adopted with a specific timetable.
WS2122 **Aprovel-EMEA/H/C/000141/WS2122/ 0185** **CoAprovel-EMEA/H/C/000222/WS2122/ 0204** **Karvea-EMEA/H/C/000142/WS2122/0187** **Karvezide-EMEA/H/C/000221/WS2122/ 0204** sanofi-aventis groupe, Lead Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 23.09.2021.	Positive Opinion adopted by consensus on 23.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2144 **Abseamed-EMEA/H/C/000727/WS2144/ 0095** **Binocrit-EMEA/H/C/000725/WS2144/ 0094** **Epoetin alfa Hexal-EMEA/H/C/000726/ WS2144/0094** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau Opinion adopted on 14.10.2021.	Positive Opinion adopted by consensus on 14.10.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2152 **Aflunov-EMEA/H/C/002094/WS2152/ 0072** **Foclivia-EMEA/H/C/001208/WS2152/ 0069** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 14.10.2021.

WS2157 **Epclusa-EMEA/H/C/004210/WS2157/0062** **Harvoni-EMEA/H/C/003850/WS2157/0102** **Sovaldi-EMEA/H/C/002798/WS2157/0076** **Vosevi-EMEA/H/C/004350/WS2157/0049** Gilead Sciences Ireland UC, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins Opinion adopted on 30.09.2021.	Positive Opinion adopted by consensus on 30.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.9. Information on withdrawn type II variation / WS procedure

WS2127 **Effentora-EMEA/H/C/000833/WS2127/0058** Teva B.V., Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Martin Huber, "To bring the RMP in line with the GVP version 2 and to update the list of safety concerns in line with the recommendation from PSUSA/00001369/201704. In addition, the outcome of PSUSA/00001369/202004 is endorsed by the MAH and the list of key messages in educational materials to include greater emphasis on explaining off-label use and its potential to lead to serious risks such as misuse, abuse and dependence are implemented. Other elements were added to promote the safe and effective use of fentanyl rapid-onset products." Withdrawal request submitted on 11.10.2021.	The MAH withdrew the procedure on 11.10.2021.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

vutrisiran - EMEA/H/C/005852, Orphan Alnylam Netherlands B.V., treatment of hereditary transthyretin-mediated amyloidosis
mavacamten - EMEA/H/C/005457 treatment of symptomatic obstructive

hypertrophic cardiomyopathy
dimethyl fumarate - EMEA/H/C/005963 treatment of multiple sclerosis
pegfilgrastim - EMEA/H/C/005810 Treatment of neutropenia
maralixibat - EMEA/H/C/005857, Orphan Mirum Pharmaceuticals International B.V., Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older
relatlimab / nivolumab - EMEA/H/C/005481 indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents (12 years and older and weighing at least 40 kg).
regdanvimab - EMEA/H/C/005854 Treatment of Covid-19
casirivimab / imdevimab - EMEA/H/C/005814 prevention and treatment of COVID-19
efbemalenograstim alfa - EMEA/H/C/005828 Reduction in the duration of neutropenia and the incidence of febrile neutropenia.
teriflunomide - EMEA/H/C/005962 treatment of multiple sclerosis (MS)
ranibizumab - EMEA/H/C/005617 treatment of neovascular age-related macular degeneration (AMD)

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/X/0044/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson "Extension application to add a new pharmaceutical form (dispersion for injection) with a new strength (0.1 mg/ml). - Update of sections 6.4, 6.5 and 6.6 of the SmPC, section 5, 6 and information for	See 4.1

healthcare professionals of the PL, section 1 of the Carton Box Label as well as section 1 and 5 of the Vial Label to ensure the correct handling by providing dose verification information about strength, age range, colour information of the flip-off plastic cap and greyscale images. - Update of section 4.2 of the SmPC to ensure the correct handling in accordance to interchangeability of the medicinal product. - Update of section 8 of the Carton Box Label to clarify expiry date "EXP" by adding storage temperature "(at -90°C to -60°C)" to ensure the correct handling of the medicinal product. - Change the name of the active substance from COVID-19 mRNA Vaccine (nucleoside modified) to Tozinameran."	
RINVOQ - upadacitinib - EMEA/H/C/004760/X/0012/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Extension application to add a strength (45 mg) of the prolonged-release tablets, grouped with a type II variation (C.I.6.a) to include the treatment of adults with moderately to severely active ulcerative colitis who had an inadequate response, lost response or were intolerant to either conventional therapy or a Biologic agent; as a consequence of the Eoi sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. The RMP (version 6.0) has also been submitted."	

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

ciltacabtagene autoleucel - EMEA/H/C/005095, Orphan, ATMP Janssen-Cilag International NV, treatment of multiple myeloma List of Questions adopted on 10.09.2021.	

B.6.4. Annual Re-assessments: timetables for adoption

Brineura - cerliponase alfa - EMEA/H/C/004065/S/0035, Orphan BioMarin International Limited, Rapporteur:	

Martina Weise, PRAC Rapporteur: Ulla Wändel Liminga

Increlex - mecasermin -
EMEA/H/C/000704/S/0070
Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka

Lojuxta - lomitapide -
EMEA/H/C/002578/S/0048
Amryt Pharmaceuticals DAC, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst

Strensiq - asfotase alfa -
EMEA/H/C/003794/S/0056, Orphan
Alexion Europe SAS, Rapporteur: Armando Genazzani, PRAC Rapporteur: Rhea Fitzgerald

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Axumin - fluciclovine (18F) -
EMEA/H/C/004197/R/0027
Blue Earth Diagnostics Ireland Limited, Rapporteur: Janet Koenig, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Rugile Pilviniene

BESPONSA - inotuzumab ozogamicin -
EMEA/H/C/004119/R/0023, Orphan
Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, Co-Rapporteur: Konstantinos Markopoulos, PRAC Rapporteur: Brigitte Keller-Stanislawski

Febuxostat Mylan - febuxostat -
EMEA/H/C/004374/R/0011
Mylan Pharmaceuticals Limited, Generic, Generic of Adenuric, Rapporteur: Elita Poplavska, PRAC Rapporteur: Jan Neuhauser

Ivabradine Accord - ivabradine -
EMEA/H/C/004241/R/0010
Accord Healthcare S.L.U., Generic, Generic of Procoralan, Rapporteur: Eleftheria Nikolaidi, PRAC Rapporteur: Menno van der Elst

Kalydeco - ivacaftor -
EMEA/H/C/002494/R/0106, Orphan
Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro, Co-

Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Maria del Pilar Rayon

Kevzara - sarilumab - EMEA/H/C/004254/R/0029

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Eva A. Segovia

Rixathon - rituximab - EMEA/H/C/003903/R/0053

Sandoz GmbH, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Anette Kirstine Stark

Riximyo - rituximab - EMEA/H/C/004729/R/0054

Sandoz GmbH, Duplicate, Duplicate of Rixathon, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Anette Kirstine Stark

Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/R/0024, ATMP

CO.DON AG, Rapporteur: Lisbeth Barkholt, Co-Rapporteur: Heli Suila, CHMP Coordinators: Kristina Dunder and Outi Maki-Ikola, PRAC Rapporteur: Brigitte Keller-Stanislawski

Trimbow - beclometasone / formoterol / glycopyrronium bromide - EMEA/H/C/004257/R/0025

Chiesi Farmaceutici S.p.A., Rapporteur: Janet Koenig, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Jan Neuhauser

Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/R/0036

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Jean-Michel Dogné

Veltassa - patiromer - EMEA/H/C/004180/R/0028

Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Kirsti Villikka

Zykadia - ceritinib - EMEA/H/C/003819/R/0042

Novartis Europharm Limited, Rapporteur: Blanca

Garcia-Ochoa, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Annika Folin

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

EXPAREL liposomal - bupivacaine - EMEA/H/C/004586/II/0005 Pacira Ireland Limited, Rapporteur: Elita Poplavska, Co-Rapporteur: Margareta Bego, PRAC Rapporteur: Rhea Fitzgerald, "Extension of indication to include children over 6 years old."
Jardiance - empagliflozin - EMEA/H/C/002677/II/0060 Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Eva A. Segovia, "Extension of indication to add the treatment of patients with Heart Failure with preserved ejection fraction based on the results from the clinical study 1245.110 EMPEROR-preserved. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC and sections 1 and 4 of the PIL are updated accordingly. Further, the MAH applied for an additional year of market protection. The updated RMP v 16.0 has also been submitted. In addition, the statement 'sodium free' was re-located from section 2 of the SmPC to section 4.4. to comply with EMA'S QRD guidance and minor linguistic changes to the national translations are included in this submission" Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0044, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include treatment of adult patients with follicular lymphoma (FL) after two or more lines of therapy who are

refractory, or relapsed during or within 6 months after completion of anti-CD20 antibody maintenance, or relapsed after autologous haematopoietic stem cell transplantation (HSCT) for Kymriah. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and corresponding sections in the Package Leaflet are updated accordingly. The RMP has been updated to version 4.0 to align with the indication extension. Lastly, the minor editorial corrections are made throughout the SmPC and package leaflet to align with the current QRD template version 10.2. ” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Olumiant - baricitinib - EMEA/H/C/004085/II/0029/G Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski, “Grouping of the following variations: C.I.6 - Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant; as a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.1 of the RMP has also been submitted. C.I.11.z - Update of the RMP (version 12.1) to change the category 3 study PASS I4V-MC-B011 end of data collection for the Atopic Dermatitis cohort and the subsequent final study report milestone .” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Xeljanz - tofacitinib - EMEA/H/C/004214/II/0039 Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, “Extension of indication to include treatment of active ankylosing spondylitis for Xeljanz prolonged release; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.1 of the RMP has also been submitted.”	

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0069/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0071 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0072/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0073/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0075/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
Erelzi - etanercept - EMEA/H/C/004192/II/0038/G Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege	
Fendrix - hepatitis B (rDNA) vaccine (adjuvanted, adsorbed) - EMEA/H/C/000550/II/0076/G GlaxoSmithKline Biologicals, Rapporteur: Christophe Focke	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0036 AstraZeneca AB, Rapporteur: Sinan B. Sarac	
Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0061/G Roche Registration GmbH, Rapporteur: Sinan B. Sarac	
Kirsty - insulin aspart - EMEA/H/C/004965/II/0003/G Mylan IRE Healthcare Limited, Rapporteur: Kirstine Moll Harboe	
Mycamine - micafungin - EMEA/H/C/000734/II/0044/G Astellas Pharma Europe B.V., Rapporteur: Janet	

Koenig

Myocet liposomal - doxorubicin hydrochloride - EMEA/H/C/000297/II/0066
Teva B.V., Rapporteur: Filip Josephson

Natpar - parathyroid hormone - EMEA/H/C/003861/II/0033/G, Orphan
Shire Pharmaceuticals Ireland Limited, Rapporteur: Karin Janssen van Doorn

Nimenrix - Meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/002226/II/0112
Pfizer Europe MA EEIG, Rapporteur: Ingrid Wang

Palynziq - pegvaliase - EMEA/H/C/004744/II/0024, Orphan
BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege

Spectrila - asparaginase - EMEA/H/C/002661/II/0026
medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop

Synflorix - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/000973/II/0166/G
GlaxoSmithkline Biologicals SA, Rapporteur: Kristina Dunder

Trogarzo - ibalizumab - EMEA/H/C/004961/II/0016/G
Theratechnologies Europe Limited, Rapporteur: Johann Lodewijk Hillege

Zutectra - human hepatitis B immunoglobulin - EMEA/H/C/001089/II/0050
Biotest Pharma GmbH, Rapporteur: Jan Mueller-Berghaus

WS2119/G
M-M-RVAXPRO-EMEA/H/C/000604/ WS2119/0110/G
ProQuad-EMEA/H/C/000622/WS2119/ 0152/G
MSD Vaccins, Lead Rapporteur: Jan Mueller-Berghaus

WS2132

Infanrix hexa-EMEA/H/C/000296/ WS2132/0305
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2138/G
Hexacima-EMEA/H/C/002702/WS2138/ 0120/G
Hexyon-EMEA/H/C/002796/WS2138/ 0124/G
Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus

WS2142
M-M-RVAXPRO-EMEA/H/C/000604/ WS2142/0111
ProQuad-EMEA/H/C/000622/WS2142/ 0153
MSD Vaccins, Lead Rapporteur: Jan Mueller-Berghaus

WS2165/G
Blitzima-EMEA/H/C/004723/WS2165/ 0048/G
Truxima-EMEA/H/C/004112/WS2165/ 0052/G
Celltrion Healthcare Hungary Kft., Duplicate, Duplicate of Truxima, Lead Rapporteur: Sol Ruiz

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Edarbi - azilsartan medoxomil - EMEA/H/C/002293/II/0030/G
Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege, "Group of variations:
· Type II C.I.4. - Update of SmPC sections 4.2, 4.8 and 5.1 with paediatric clinical data from study AR14.001 (PIP study 8) following the outcome of procedure EMEA/H/C/002293/P46/012.
· Type II C.I.4. - Update of SmPC section 5.2 with paediatric clinical data from study TAK-491_109 (PIP study 7) following the outcome of procedure EMEA/H/C/002293/P46/011.
· Type II C.I.4. - Update of SmPC section 5.3 with data from juvenile animal toxicity studies.
· Type II C.I.4. - Update of SmPC section 4.5 with drug-drug interaction information from clinical pharmacology studies TAK-491-013 and

TAK-563-004.
Furthermore, the MAH is taking the opportunity to update the PI in line with the latest QRD template version 10.2, update the local representatives for Ireland, Slovenia and United Kingdom in the Package Leaflet (PL) and update minor editorial/typographical to Product information."

Evrysdi - risdiplam - EMEA/H/C/005145/II/0003, Orphan
Roche Registration GmbH, Rapporteur: Bruno Sepodes, "Update of section 4.8 of the SmPC to add undesirable effects based on post-marketing experience. The Package Leaflet (PL) is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the contact details of local representatives in the PL."

Fasenra - benralizumab - EMEA/H/C/004433/II/0039
AstraZeneca AB, Rapporteur: Fátima Ventura, "C.I.4
Update of section 5.1 in order to include information on the maintenance of long-term safety based on the results from study D3250C00037 (MELTEMI) listed as a category 3 study in the RMP. This is a multicenter, open-label safety extension study to evaluate the safety and tolerability of a fixed 30 mg dose of benralizumab in adults with severe asthma. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.2."

Ganfort - bimatoprost / timolol - EMEA/H/C/000668/II/0038
Allergan Pharmaceuticals Ireland, Rapporteur: Kirstine Moll Harboe, "C.I.4
Update of section 4.8 of the SmPC in order to add periorbital and lid changes associated with periorbital fat atrophy and skin tightness to the list of adverse drug reactions (ADRs) with frequency uncommon."

Keytruda - pembrolizumab - EMEA/H/C/003820/II/0114
Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of section 5.1 of the SmPC in order to update efficacy

information based on final results from study KEYNOTE-087 listed as an imposed PAES in the Annex II; this is a multicenter, single-arm, multi-cohort, non-randomized Phase 2 study of IV pembrolizumab in participants with relapsed or refractory classical Hodgkin lymphoma (cHL)."	
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0115 Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-426 listed as imposed PAES in the Annex II; this is a Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)."	
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0116 Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-177 listed as PAES in Annex II of the Product Information; this is a 2-arm, multicenter, international, randomized, open-label, Phase 3 study evaluating the efficacy and safety of pembrolizumab monotherapy versus globally-accepted SOC therapies for Colorectal carcinoma (CRC) in participants with locally confirmed Deficient mismatch repair (dMMR) or Microsatellite instability-high (MSI-H) unresectable or metastatic CRC who have not received prior chemotherapy for their disease."	
Kovaltry - octocog alfa - EMEA/H/C/003825/II/0038 Bayer AG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of the SmPC sections 4.8 and 5.1 to include data from the LEOPOLD Kids Part B (previously submitted as Art 46; an addendum on biomarker data is included in this submission) and extension study results included as part of this submission. In addition, an editorial revision in section 4.2 and a	

clarification in section 6.5 of the SmPC are proposed. Section 4 of the Package is updated accordingly. A correction of a typo in the Greek product information is also included. The Risk Management Plan for Kovaltry is updated using Revision 2.0.1 of the template format."	
Ocrevus - ocrelizumab - EMEA/H/C/004043/II/0030 Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe, "to include new clinical efficacy data in section 5.1 of the SmPC to reflect on the newly available post hoc pooled analyses results related to the time-to-walking aid data performed on clinical studies WA21092 (OPERA I) and WA21093 (OPERA II) in the RMS population."	
Oxlumo - lumasiran - EMEA/H/C/005040/II/0007, Orphan Alnylam Netherlands B.V., Rapporteur: Martina Weise, "Update of section 5.3 of the SmPC in order to update the non-clinical information based on the final results from the 26-week GLP carcinogenicity study of lumasiran by subcutaneous injection in TgRasH2 mice, as agreed as part of protocol assistance (EMEA/H/SA/4014/2/2019/PA/PR/I). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."	
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0067 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of section 4.8 of the SmPC in order to include the new ADR of rhinorrhoea identified in the IMpassion031 study and reviewed in the context of a drug safety report. The package leaflet is proposed to be updated accordingly. Additional amendments are proposed to the footnotes of ADRs in the SmPC, the removal of the term 'lung infection', the inclusion of the term 'orthostatic hypertension' and the inclusion of a new footnote listing the terms covered for the ADR of psoriasis."	
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) -	

EMEA/H/C/003982/II/0090
MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 4.8 of the Summary of Product Characteristics (SmPC) in order to add Convulsions with or without fever with frequency Not known to the list of post-marketing adverse events. The package leaflet (PL) is updated accordingly."

Veklury - remdesivir - EMEA/H/C/005622/II/0026/G
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Grouped variation updating sections 5.2 and 5.3 of the SmPC in order to add additional pharmacokinetic (PK) data coming non clinical and clinical studies to fulfil two Post-Authorisation Measures for Veklury: Recommendation (REC) number 4 (non-clinical data to further characterise a previously unidentified metabolite, M27); and REC number 7 (to submit data from additional analysis of the circulating species of remdesivir from the human mass-balance study, GS-US-399-4231). Both were agreed during the initial conditional marketing application (EMEA/H/C/005622)."

VITRAKVI - larotrectinib - EMEA/H/C/004919/II/0021
Bayer AG, Rapporteur: Filip Josephson, Co-Rapporteur: Alexandre Moreau, "Update of section 5.2 of the SmPC in order to reflect the outcome of an updated analysis of the population pharmacokinetic (PopPk) model based on additional PK sampling in patients aged 1 month to 6 years from study LOXO-TRK-15003 (SCOUT) imposed as a specific obligation (SOB). The MAH is also proposing to delete this SOB from Annex II. The MAH took the opportunity of this variation to introduce corrections to section 4.8 of the SmPC and to Annex II."

WS2145
DuoPlavin-EMEA/H/C/001143/WS2145/0059
Iscover-EMEA/H/C/000175/WS2145/0145
Plavix-EMEA/H/C/000174/WS2145/0143
sanofi-aventis groupe, Lead Rapporteur: Bruno Sepodes, "Update of section 4.5 of the SmPC to add the drug-drug interaction between clopidogrel and rosuvastatin based on a review

of the available data including literature and the MAH safety database. The package leaflet is updated accordingly."	
WS2154 **CONTROLOC Control-EMEA/H/C/001097/ WS2154/0038** **PANTOLOC Control-EMEA/H/C/001100/ WS2154/0043** **PANTOZOL Control-EMEA/H/C/001013/ WS2154/0040** **SOMAC Control-EMEA/H/C/001098/ WS2154/0039** Takeda GmbH, Lead Rapporteur: Romaldas Mačiulaitis, "C.1.4 - Update of section 4.8 of the SmPC to update the existing term "Interstitial nephritis" to "Tubulointerstitial nephritis (TIN)" in line with the updated Company Core Data Sheet. In addition, section 4.4 of the SmPC for centralised authorised products is updated with the Excipient warning for Sodium as per EMA guideline EMA/CHMP/302620/2017/EN Rev. 1. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the PL and to bring the PI in line with the last QRD template (version 10.1). This procedure also includes NAPs as listed in Annex B."	

B.6.10. CHMP-PRAC assessed procedures

Erleada - apalutamide - EMEA/H/C/004452/II/0017 Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 5.3 of the SmPC in order to update non-clinical information based on final results from study TOX11338 listed as PAM (EMEA/H/C/004452/MEA/006); this is a 2-year carcinogenicity study of JNJ-56021927-AAA by oral gavage in rats; The RMP version 4.1 has also been submitted. In addition, the MAH has taken this opportunity to include general information in the RMP regarding study TITAN (PCR3002)."	
Hemlibra - emicizumab -	

EMEA/H/C/004406/II/0028
Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ilaria Baldelli, "Submission of the final study report for BO40853 (Hemlibra Survey to Prescribers and Patients/Carers to Evaluate Awareness, Knowledge, and Compliance to Additional Risk Minimization Measures, listed as a category 3 study in the RMP). An updated RMP (version 4.0) is presented in support of this application."

Imraldi - adalimumab -
EMEA/H/C/004279/II/0048/G
Samsung Bioepis NL B.V., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Ulla Wändel Liminga

Tecentriq - atezolizumab -
EMEA/H/C/004143/II/0066
Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.13: Submission of the final report from study WO29635 to fulfil a category 3 study activity (MEA/FSR 007). This is A Phase IB/II study of the safety and pharmacology of
Atezolizumab administered with or without Bacille Calmette-Guérin in patients with High Risk Non-Muscle-Invasive Bladder Cancer. The RMP version 22.0 has also been submitted. The RMP has additionally been amended to revise the due date for the submission of the final CSR for study MO39171 (TAIL)."

Tresiba - insulin degludec -
EMEA/H/C/002498/II/0054
Novo Nordisk A/S, Rapporteur: Kristina Dunder, Co-Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Annika Folin, "Update of sections 4.6 and 5.1 of the summary of product characteristics in order to include new clinical data from the pregnancy trial EXPECT conducted for Tresiba.
The Package Leaflet is updated in accordance. The RMP version 9.0 is also submitted."

Uptravi - selexipag -
EMEA/H/C/003774/II/0034
Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 4.8 of the SmPC to add 'dyspepsia' as a new ADR with frequency

'common', and to include further information on the frequency of 'dyspepsia' and 'anaemia' specific to initial 2-step triple combination therapy, based on the studies AC-065A308 (TRITON) and AC-065A404 (TRACE). AC-065A308 (TRITON) study was a randomized, double-blind, placebo-controlled, parallel-group, Phase 3b, efficacy and safety study comparing triple oral combination therapy (selexipag, macitentan, tadalafil) with double oral combination therapy (placebo, macitentan, tadalafil) in newly diagnosed, treatment-naïve participants with PAH. The AC-065A404 (TRACE) study was a randomized, double-blind, placebo-controlled, parallel-group, exploratory Phase 4 study in participants with PAH to assess the effect of selexipag on daily life physical activity and participant's self-reported symptoms and their impacts. The package leaflet is updated accordingly. A revised RMP version 9.2 was provided as part of the application."

B.6.11. PRAC assessed procedures

PRAC Led
Adasuve - loxapine - EMEA/H/C/002400/II/0033
Ferrer Internacional s.a., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update safety information on Bronchospasm based on final results from study AMDC-204-401 EU PASS (assessed in procedure EMEA/H/C/0002400/II/0032): Post-authorisation Observational Study to Evaluate the Safety of ADASUVE (Staccato loxapine for inhalation) in Agitated Persons in Routine Clinical Care, a category 3 study in the RMP; the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

PRAC Led
Evenity - romosozumab - EMEA/H/C/004465/II/0010
UCB Pharma S.A., Rapporteur: Kristina Dunder,

PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of an updated RMP version 2.0 in order to remove the important identified risk of "immunogenicity", based on the Good Pharmacovigilance Practices (GVP) guidelines, EMA guidance on immunogenicity assessment, and the available non-clinical, clinical and post-marketing data. In addition, following the Pharmacovigilance Risk Assessment Committee (PRAC) recommendation (EMA/PRAC/265359/2021) dated 06 May 2021, the MAH is taking this opportunity to add "cardiac arrythmia" as an important potential risk of romosozumab, update the protocol for the ongoing post authorization safety study (PASS) OP0004 to include cardiac arrhythmias as specific events to monitor, and include a targeted follow-up questionnaire related to cardiac arrhythmias in the RMP Part VII Annex 4.
The MAH is also taking this opportunity to introduce minor changes in the PASS protocols of three studies OP0004, OP0005 and OP0006."

PRAC Led

Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0023

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of section 4.6 of the SmPC in order to update information on Pregnancy Registry 130_110B, listed as a category 3 study in the RMP. The PL is updated accordingly. The RMP version 3.1 has also been submitted in order to update information related to the pregnancy study, clinical and post-marketing exposure."

PRAC Led

Latuda - lurasidone - EMEA/H/C/002713/II/0036

Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Filip Josephson, "Update of section 4.8 of the SmPC to amend the frequency of ADRs in adults and to add 'syncope' (frequency uncommon) and 'cerebrovascular accident' (frequency rare) following the assessment of the procedure

EMEA/H/C/PSUSA/00010114/202010. The Package Leaflet is updated accordingly. Minor adjustments of the PTs based on the MedDRA definitions were implemented and the ADR 'blood creatine phosphokinase increased' was moved to the SOC Investigations. In addition, the marketing authorisation holder has taken the opportunity to combine all the dosages in a single version of the SmPC, to update the list of local representatives in the PL and to bring the PI in line with the latest QRD template version 10.2 Rev. 1."

PRAC Led

Prolia - denosumab - EMEA/H/C/001120/II/0091/G

Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "- C.I.11.b: Submission of an updated RMP version 28.0 in order to remove osteonecrosis outside the jaw (OOJ) including external auditory canal (OEAC) as an important potential risk. - C.I.11.b: Submission of an updated RMP version 28.0 in order to remove immunogenicity following a significant change to the manufacturing process as missing information. - C.I.11.b: Submission of an updated RMP version 28.0 in order to introduce changes to the category 3 PASS-retrospective cohort database study (study 20190038) for the potential increased risk of cardiovascular and cerebrovascular events among women with PMO and men with osteoporosis by adding the study objectives. In addition, the MAH took the opportunity to update the RMP in order to provide the date for the provision of the final study report for study 20190038 and to include the post-marketing exposure data from the last submitted PSUR/PBRER (#13)."

PRAC Led

Prolia - denosumab - EMEA/H/C/001120/II/0092

Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study 20190038 "Incidence of Cardiovascular and Cerebrovascular Events Among Postmenopausal Women and Men With Osteoporosis Who

Initiated Treatment With Denosumab or Zoledronic Acid - a Retrospective Cohort Study". This is an observational PASS listed as category 3 study in the RMP."

PRAC Led

TRISENOX - arsenic trioxide - EMEA/H/C/000388/II/0076

Teva B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Update of section 4.6 of the SmPC in order to update information on pregnancy and contraception in male patients following the decision and discussion made for EMEA/H/C/PSUSA/00000235/202009. The Package Leaflet is updated accordingly."

PRAC Led

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0038

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Submission of the final report from study MS1222-0003 ''Assessment of anti-PF4 antibodies prior to, and following, vaccination with AZD1222" listed as a category 3 study in the RMP. This is a study where sera of vaccinated individuals in study D8110C00001 are tested to elucidate whether vaccination with Vaxzevria leads to increased levels of circulating anti-PF4 antibodies, a key component of the hypothesized mechanism underlying thrombosis with thrombocytopenia syndrome (TTS)."

PRAC Led

Xeljanz - tofacitinib - EMEA/H/C/004214/II/0044

Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "C.I.3.b - Update of sections 4.4, 4.8 and 5.1 to add warnings and safety data on serious infections, viral reactivation, non-melanoma skin cancer and fractures. This is based on the final results from study A3921133 listed as a category 3 study in the RMP; this is a post-authorisation safety study conducted to evaluate the safety of tofacitinib 5 mg and 10 mg compared to TNFi in adults' subjects aged ≥50 years with moderately or severely active

RA and with at least 1 additional CV risk factor. The Package Leaflet is updated accordingly. The RMP version 21.1 has also been submitted.
In addition, the MAH took the opportunity to update the Outer carton (section 4 for oral solution) to include a total volume of 240 mL as requested following the completion of the procedure EMEA/H/C/004214/X/0024/G."

PRAC Led

WS2158

Exviera-EMEA/H/C/003837/WS2158/0051

Viekirax-EMEA/H/C/003839/WS2158/0063

AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "To update the Annex IID study milestone due date for the hepatocellular carcinoma (HCC) recurrence post-authorisation safety study (B20-146) following the EMA's recommendation on 6 July 2021.
In addition, the MAH is taking the opportunity to introduce few minor linguistic and typographical corrections in the Summary of Product Characteristics (SmPCs) for the Hungarian, Latvian and Romanian translations of the Exviera product information."

B.6.12. CHMP-CAT assessed procedures

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2131

Herceptin-EMEA/H/C/000278/WS2131/0176

Kadcyla-EMEA/H/C/002389/WS2131/0060

Phesgo-EMEA/H/C/005386/WS2131/0009

Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2139

Hexacima-EMEA/H/C/002702/WS2139/0121
Hexyon-EMEA/H/C/002796/WS2139/0125
Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus

WS2147
Infanrix hexa-EMEA/H/C/000296/WS2147/0306
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2148/G
Hexacima-EMEA/H/C/002702/WS2148/0122/G
Hexyon-EMEA/H/C/002796/WS2148/0126/G
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

WS2161
Mircera-EMEA/H/C/000739/WS2161/0085
NeoRecormon-EMEA/H/C/000116/WS2161/0114
Roche Registration GmbH, Lead Rapporteur: Martina Weise

WS2171
Glyxambi-EMEA/H/C/003833/WS2171/0040
Synjardy-EMEA/H/C/003770/WS2171/0058
Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "To update section 4.8 of the SmPC and section 4 of the PL to include the side effect 'constipation' in order to align with the Jardiance PI following approval of EMEA/H/C/002677/II/0055."

WS2172
Aprovel-EMEA/H/C/000141/WS2172/0186
CoAprovel-EMEA/H/C/000222/WS2172/0205
Karvea-EMEA/H/C/000142/WS2172/0188
Karvezide-EMEA/H/C/000221/WS2172/0205
sanofi-aventis groupe, Lead Rapporteur: Maria Concepcion Prieto Yerro

WS2176

Enurev Breezhaler-EMEA/H/C/002691/ WS2176/0039 **Seebri Breezhaler-EMEA/H/C/002430/ WS2176/0039** **Tovanor Breezhaler-EMEA/H/C/002690/ WS2176/0043** Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe, "To update the PI for Seebri Breezhaler (glycopyrronium bromide) and its two duplicates, Enurev Breezhaler and Tovanor Breezhaler in line with current QRD template v10.2, Rev. 1 and QRD template v10.1 as follows: - Package leaflet is updated to include Northern Ireland in the list of the local representatives of the Marketing Authorisation Holder (QRD v10.2) - ANNEX II (C and D sections) and Labelling are updated in line with the QRD template v10.1. The MAH also updated section 4.4 (subsection 'Excipients') of the SmPC (Annex I) to change the word from "the Lapp" to "total" to align with the latest European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668), dated 22-Nov-2019. In addition, the MAH has taken the opportunity to update the Instructions for use (IFU) in section 6.6 of the SmPC (Annex I) and also at the end of the Package leaflet."	
WS2178/G **Aflunov-EMEA/H/C/002094/WS2178/ 0074/G** **Foclivia-EMEA/H/C/001208/WS2178/ 0071/G** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani	
WS2179/G **Prezista-EMEA/H/C/000707/WS2179/ 0114/G** **Rezolsta-EMEA/H/C/002819/WS2179/ 0045/G** **Symtuza-EMEA/H/C/004391/WS2179/ 0039/G** Janssen-Cilag International NV, Lead Rapporteur: Johann Lodewijk Hillege	
WS2180 **Aprovel-EMEA/H/C/000141/WS2180 /0187** **CoAprovel-EMEA/H/C/000222/WS2180/**	

0206
Karvea-EMEA/H/C/000142/WS2180/0189
Karvezide-EMEA/H/C/000221/WS2180/
0206
sanofi-aventis groupe, Lead Rapporteur: Maria Concepcion Prieto Yerro

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. Timetables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.1.1. List of procedures concluding at 11-14 October 2021 CHMP plenary:

Endocrinology-Gynaecology-Fertility-Metabolism	
Pabinafusp alfa (JR-141) Treatment of Mucopolysaccharidosis type II (MPS II)	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Treatment of Niemann-Pick disease, Type C (NPC) (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Type 1 diabetes	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Neurology	
Treatment of Alzheimer's disease	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Ophtalmology	
Leber's Hereditary Optic Neuropathy (LHON) associated with ND4 G11778A mutation. ATMP	The CAT and the CHMP denied eligibility to PRIME and adopted the critical summary report.
Haematology – Hemostaseology	
Treatment of polycythaemia vera (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.

G.1.2. List of procedures starting in October 2021 for November 2021 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address